Top

Vicente Valero, M.D., F.A.C.P.

Department of Breast Medical Oncology, Division of Cancer Medicine

About Dr. Vicente Valero

Dr. Valero has been with The University of Texas M. D. Anderson Cancer Center since June 1991, obtaining his M.D. from the Universidad Autonoma de Nuevo Leon, Facultad de Medicine, in 1980. Postgraduate training in Internal Medicine was completed at St. Elizabeth Hospital in Youngstown, Ohio, and Northeastern Ohio University College of Medicine in Rootstown, Ohio. Fellowships in Hematology-Medical Oncology were completed at the University of Cincinnati, Ohio, and at The University of Texas Medical Branch in Galveston, Texas. Board certifications include the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology.

Publications include over 150 published articles in peer-reviewed journals, editorials and invited articles, 13 book chapters, and over 100 abstracts. He is an actively involved teacher in the Medical Oncology Continuing Clinic for Fellows and medical oncology and internal medicine residents at Lyndon B. Johnson General Hospital and The University of Texas M. D. Anderson Cancer Center, where he was honored as the Division of Medicine Teacher of the Year for the 1993-1994 and 1996-1997 academic years, and the Educator of the Month for December 2003. He is the primary investigator for several ongoing funded research protocols, and as an acknowledged leader in his fields of interest, he is a popular and much sought after speaker for local, national, and international presentations, and has given over 250 presentations, maintaining his belief that sharing all facets of the knowledge of breast cancer with other treating physicians and healthcare providers and educating the public about this disease may translate to improvement in its prevention, early detection, and treatment.

Primary Appointment

Deputy Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Dr. Valero utilizes a multidisciplinary approach to the treatment of breast cancer. His research interests include breast neoplasms, unusual histologies, new drug development, minority groups, and clinical trials with angiogenesis. More specifically, his primary focus is in the area of Her-2 neu amplified and ER+ HER-2 normal early, as well as metastatic breast cancer and novel biological agents, the management of patients with locally advanced breast cancer utilizing new biological agents and gene profiling, and clinical research targeting minority populations

Education & Training

Degree-Granting Education

1980	Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Monterrey, MX, MD

Postgraduate Training

1987-1988	Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Texas Medical Branch, Galveston, Texas
1985-1987	Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Cincinnati Medical Center and Veterans Administration Hospital, Cincinnati, Ohio
1982-1985	Internal Medicine: Resident, Internal Medicine, Saint Elizabeth Hospital Medical Center; Northeastern Ohio University College of Medicine, Youngstown; Rootstown, Ohio
1982-1985	Internal Medicine: Resident, Internal Medicine, Northeastern Ohio University College of Medicine, Rootstown, Ohio

Board Certifications

1988	American Board of Hematology
1987	American Board of Medical Oncology
1985	American Board of Internal Medicine

Experience & Service

Academic Appointments

Associate Director, Department of Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2019

Chairman Ad Interim, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2014

Clinical Director, Department of The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2021

Deputy Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2012

Professor of Internal Medicine, The University of Texas Health Science Center, Houston, TX, 2003 - 2010

Associate Professor, The University of Texas Health Science Center, Houston, TX, 2001 - 2003

Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2002

Assistant Professor, The University of Texas Health Science Center, Houston, TX, 1995 - 2001

Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1994 - 1997

Assistant Professor of Medicine, Assistant Internist, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991 - 1994

Instructor, The University of Texas Health Science Center, Houston, TX, 1991 - 1993

Assistant Clinical Professor of Medicine, Department of Medicine, The University of Texas Medcial Branch, Galveston, TX, 1989 - 1992

Assistant Professor, Department of Medicine, The University of Texas Medcial Branch, Galveston, TX, 1988 - 1989

Instructor, The University of Texas Medical Branch, Galveston, TX, 1987 - 1989

Instructor, University of Cincinnati College of Medicine, Cincinnati, OH, 1985 - 1987

Other Appointments/Responsibilities

Director of Medical Oncology Research, Lyndon B. Johnson General Hospital, Houston, TX, 2007 - 2009

Member, German Adjuvant Breast Cancer Study Group (GABG) Independent Data Monitoring Committee for GABG 12 Study, Houston, TX, 2002 - 2005

Member, The University of Texas MD Anderson Cancer Center and Harris County Hospital District, Workteam for Managed Care Approach for the Indigent Population, Houston, TX, 2001 - 2010

Faculty Member, International Oncology Foundation (IOF), Houston, TX, 2001 - 2005

Physician Medical Oncology Affiliate to Kelsey-Seybold Clinic, The University of Texas MD Anderson Physicians Network, Houston, TX, 1999 - 2002

Oncology Representative, Executive Committee, Lyndon B. Johnson General Hospital, Houston, TX, 1995 - 2007

Chief of Oncology, Lyndon B. Johnson General Hospital, Houston, TX, 1995 - 2007

M.D., Hematologist-Oncologist, Texas Oncology, Valley Oncology, P.A, Harlingen/Brownsville, TX, 1989 - 1991

Institutional Committee Activities

Member, Surgery Division Head Search Committee, 2013 - Present

Member, Breast Multidisciplinary Planning Conference - MDACC and MDAPN, 2010 - 2010

Alternate Representative, Fellowship Committee, 2009 - 2012

Chairman, Breast Medical Oncology Monday Noon Conference, 2008 - 2012

Member, Inflammatory Breast Cancer Research Program & Clinic, 2008 - Present

Member, MDACC Steering Committee on Sister Institution with Instituto Nacional de Cancerologia de Mexico (INCAN), 2006 - 2010

Member, Partnership for Excellence in Cancer Research MDACC & University of Puerto Rico, Shared Resources Core Matching Committee, 2005 - 2010

Member, Cardiology and Oncology Steering Committee for meeting "Cancer and Cardiovascular Disease: Increasing the Success of Chemotherapy by Reducing Cardiovascular Disease as a Barrier and Long-Term Risk", 2005 - 2006

Member, Faculty Achievement Award in Patient Care Committee, 2005

Member, Search Committee for Chair, Department of Health Disparities, 2003 - 2004

Member, Minority Recruitment and Research Committee, 2003 - 2007

MDACC Medcal Oncology Coordinator, NSABP, 2003 - 2010

Member, External Joint Operations Committee, 2002 - 2005

Member, Institutional Research Grants Program Oversight Committee, 2002 - 2004

Member, Promotion and Tenure Committee, 2002 - 2005

Member, IRB Surveillance Committee, 2001 - 2004

Department Representative, Breast Practice Guidelines Group, 2000 - 2005

Member, Breast Cancer Working Group, 2000 - 2001

Member, Steering Committee on Cancer and Minorities, 1998 - 1999

Member, Case Management Executive Committee, 1996 - 1997

Member, Utilization and Case Management Committee, 1996 - 1997

Representative for BMO/General Oncology, Fellowship Committee, 1995 - 2009

Honors & Awards

2023	R. Lee Clark Prize, MD Anderson Cancer Center
2022	Castle Connolly Top Doctor Recognition 2022, Castle Connolly
2022	Professor Honorarium, Congress of the Latin American Federation of Mastology
2010	The University Cancer Foundation Faculty Achievement Award in Patient Care, UT Faculty Senate
2008	America's Top Oncologists, Consumers' Research Council of America
2007	Gerald P. Bodey Award for Excellence in Education, UT MDACC - Div of Cancer Medicine
2006	America's Top Doctors for Cancer, Castle Connolly Medical Ltd
2006	Best Doctors in America, www.bestdoctors.com
2006	Houston's Top Doctors, H TEXAS magazine
2005	Texas Super Doctors, Texas Monthly, December issues
2003	Educator of the Month, The University of Texas M. D. Anderson Cancer Center
2002	Who's Who in Medicine and Healthcare, 4th Ed, Marquis Who's Who, New Providence, NJ
2002	Who's Who in Science and Engineering, 7th Ed, Marquis Who's Who, New Providence, NJ
2001	America's Top Doctors, 1st-7th editions, JJ Connolly (Ed.), Castle Connolly Medical Ltd., New York, NY
2001	Fellow, American College of Physicians
2001	Top Breast Cancer Doctors in America, Redbook 197(4):30-42, October 2001
1993	Teacher of the Year Award, 1993 and 1996, The University of Texas M. D. Anderson Cancer Center
1979	Medical School, Senior Year, Universidad Autonoma de Nuevo Leon, Facultad de Medicina

Professional Memberships

Fundación Grupo Español de Investigación en Cáncer de Mama / Spanish Breast Cancer Research Group Foundation (GEICAM / CIBOMA)

2010

Texas Society of Medical Oncology

2008 - 2009

Texas Society of Medical Oncology

2007 - 2008

Societe Internationale de Senologie

2007 - 2008

American College of Physicians

2001

Selected Publications

Peer-Reviewed Articles

Hennessy MA, Cimino-Mathews A, Carter JM, Kachergus JM, Ma Y, Leal JP, Solnes LB, Denbow R, Abramson VG, Carey LA, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Winer EP, Krop IE, Wolff AC, Wahl RL, Perez EA, Huang CY, Stearns V, Thompson EA, Connolly RM. Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response. JCO Precis Oncol 9:e2400546, 2025. e-Pub 2025. PMID: 40179327.
Kuerer HM, Valero V, Smith BD, Krishnamurthy S, Diego EJ, Johnson HM, Lin H, Shen Y, Lucci A, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Hunt KK, Yang WT, Rauch GM. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol, 2025. e-Pub 2025. PMID: 40152443.
Xu Z, Zhou Z, Son JB, Feng H, Adrada BE, Moseley TW, Candelaria RP, Guirguis MS, Patel MM, Whitman GJ, Leung JWT, Le-Petross HTC, Mohamed RM, Panthi B, Lane DL, Chen H, Wei P, Tripathy D, Litton JK, Valero V, Huo L, Hunt KK, Korkut A, Thompson A, Yang W, Yam C, Rauch GM, Ma J. Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Cancers (Basel) 17(6), 2025. e-Pub 2025. PMID: 40149299.
Hennessy MA, Cimino-Mathews A, Carter JM, Kachergus JM, Ma Y, Leal JP, Solnes LB, Abramson VG, Carey LA, Rimawi M, Specht J, Storniolo AM, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff AC, Wahl RL, Huang CY, Stearns V, Thompson EA, Connolly RM. A composite (18)F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast 81:104432, 2025. e-Pub 2025. PMID: 40049115.
Mukhtar RA, Gottipati S, Yau C, Lopez-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Lae M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martin M, Del Monte-Millan M, Boughey JC, Goetz MP, Hoskin T, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Provenzano E, Sammut SJ, Thomas JS, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, J van 't Veer L, Cameron D, Esserman LJ, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. NPJ Breast Cancer 11(1):14, 2025. e-Pub 2025. PMID: 39948079.
Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res, 2025. e-Pub 2025. PMID: 39841861.
Yennurajalingam S, Valero V, Smalgo BG, Overman MJ, Dasari A, Wolff RA, Raghav KPS, Barcenas CH, Busaidy NL, Fellman B, Basen-Engquist K, Hess KR, Tripathy D, Bruera E. Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw 23(1), 2025. e-Pub 2025. PMID: 39773433.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol 32(1):123-124, 2025. e-Pub 2025. PMID: 39443343.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol 32(1):84-91, 2025. e-Pub 2025. PMID: 39419889.
Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open 9(11):103973, 2024. e-Pub 2024. PMID: 39500139.
Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study. Cancer Res Commun, 2024. e-Pub 2024. PMID: 39356138.
Mitchell MP, Shaitelman SF, Smith BD, Krishnamurthy S, Valero V, Rauch GM, Shen Y, Lin H, Kuerer HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol 50(12):108613, 2024. e-Pub 2024. PMID: 39243728.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. ASO Visual Abstract: Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes on Targeted Axillary Dissection. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 39090492.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 39044106.
Waks AG, Chen EL, Graham N, Frey AM, Almeida K, Attaya V, Ryding C, Abbass I, Fung A, Sussell J, Cortazar P, Harvey C, Leth D, Faggen M, Sinclair N, Walsh J, Tung N, Sinclair S, Lo S, Yardley D, Valero V, Meisel J, Ballinger TJ, Adams S, Carey LA, Rauch JK, Abramson VG, Williams NO, Chen WY, Leone JP, Schumer ST, Tayob N, Tolaney SM. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial). JCO Oncol Pract:OP2400021, 2024. e-Pub 2024. PMID: 39028923.
Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol:JCO2302170, 2024. e-Pub 2024. PMID: 38935923.
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med 5(6):101595, 2024. e-Pub 2024. PMID: 38838676.
Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res 30(11):2424-2432, 2024. e-Pub 2024. PMID: 38629963.
Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys 118(2):443-454, 2024. e-Pub 2024. PMID: 37802228.
Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging, 2024. e-Pub 2024. PMID: 38294179.
Hennessy MA, Leal JP, Huang CY, Solnes LB, Denbow R, Abramson VG, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Winer EP, Krop IE, Wolff AC, Cimino-Mathews A, Wahl RL, Stearns V, Connolly RM. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer. J Nucl Med 64(11):1690-1696, 2023. e-Pub 2023. PMID: 37652539.
Adesoye, T, Everidge, S, Chen, J, Sun, SX, Teshome, M, Valero, V, Woodward, W, Lucci, A. Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Annals of surgical oncology 30(10):6232-6240, 2023. e-Pub 2023. PMID: 37479842.
Xu, Z, Rauch, DE, Mohamed, RM, Pashapoor, S, Zhou, Z, Panthi, B, Son, JB, Hwang, K, Musall, BC, Adrada, BE, Candelaria, RP, Leung, J, Le-Petross, H, Lane, DL, Perez, F, White, JB, Clayborn, A, Reed, BJ, Chen, H, Sun, J, Wei, P, Thompson, A, Korkut, A, Huo, L, Hunt, KK, Litton, J, Valero, V, Tripathy, D, Yang, W, Yam, C, Ma, J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835523.
Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health, 2023. e-Pub 2023. PMID: 37795002.
Adesoye T, Everidge S, Chen J, Sun SX, Valero V, Woodward WA. ASO Visual Abstract: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Annals of Surgery, 2023. e-Pub 2023.
Johnson HM, MD, Lin H, PhD, Shen Y, PhD, Diego EJ, MD, Krishnamurthy S, MD, Yang WT, MBBS, MHM, Smith BD, MD, Valero V, MD, Lucci A, MD, Sun SX, MD, MS, Shaitelman SF, MD, EdM, Mitchell MP, MD, PhD, Boughey JC, MD, White RL, MD, Rauch GM, MD, PhD, Kuerer HM, MD, PhD, Study Group FTER. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA, 2023. e-Pub 2023. PMID: 37707811.
Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg 237(1):101-108, 2023. e-Pub 2023. PMID: 36856291.
Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc 2023:1-4, 2023. e-Pub 2023. PMID: 38083160.
Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Kai M, Song J, Shen Y, Willey JS, Lim B, Valero V, Ueno NT, Reuben JM. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900406.
Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831368.
Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
Martinez-Cannon BA, Soto-Perez-de-Celis E, Erazo Valle-Solis A, Arce-Salinas C, Bargallo-Rocha E, Bautista-Piña V, Cervantes-Sanchez G, Flores-Balcázar CH, Lara Tamburrino MDC, Lluch A, Maffuz-Aziz A, Pérez-Sánchez VM, Poitevin-Chacón A, Salas-González E, Torrecillas Torres L, Valero V, Villaseñor-Navarro Y, Cárdenas-Sánchez J. Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study. Clin Transl Oncol 25(1):151-159, 2023. e-Pub 2023. PMID: 35986133.
Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 13:1264259, 2023. e-Pub 2023. PMID: 37941561.
Musall, BC, Adrada, BE, Candelaria, RP, Mohamed, RM, Abdelhafez, AH, Son, JB, Sun, J, Santiago, L, Whitman, GJ, Moseley, T, Scoggins, ME, Mahmoud, H, White, JB, Hwang, K, Elshafeey, N, Boge, M, Zhang, S, Litton, J, Valero, V, Tripathy, D, Thompson, A, Yam, C, Wei, P, Moulder, S, Pagel, MD, Yang, WT, Ma, J, Rauch, GM. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Journal of Magnetic Resonance Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
Sella T, Zheng Y, Tayob N, Ruddy KJ, Freedman RA, Dang C, Yardley D, Isakoff SJ, Valero V. Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ, 2022. e-Pub 2022. PMID: 36450763.
Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncology, 2022. e-Pub 2022. PMID: 36306810.
ChengyueWu, AngelaMJarrett, ZijianZhou, NabilElshafeey, BeatrizEAdrada, RosalindPCandelaria, RaniaMMMohamed, MedineBoge, LeiHuo, JasonBWhite, DebuTripathy, VicenteValero. MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Research, 2022. e-Pub 2022. PMID: 35914239.
Yam C, Abuhadra N, Sun R, Ding Q, White J, Ravenberg E, Clayborn A, Valero V, Tripathy D, Damodaran S, Arun B, Litton J, Ueno N, Murthy R, Lim B, Baez L, Li X, Buzdar A, Hortobagy G, Thompson A, Mittendorf E, Rauch G, Candelaria R, Adrada B, Huo L, Moulder-Thompson S, Chang AJ. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clinical Cancer Research, 2022. e-Pub 2022.
Yam, Abuhadra N, Sun R, Ding Q, White J, Ravenberg E, Clayborn A, Valero V, Tripathy D, Damodaran S, Arun B, Litton J, Ueno N, Murthy R, Lim B, Baez L, Li X, Buzdar A, Hortobagy G, Thompson A, Mittendorf E, Rauch G, Candelaria R, Adrada B, Huo L, Moulder-Thompson S, Chang AJ. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clinical Cancer Research. Clinical Cancer Research, 2022. e-Pub 2022.
ClintonYam, NourAbuhadra, RyanSun, BeatrizEAdrada, Qing-QingDing, JasonBWhite, ElizabethERavenberg, AlysonRClayborn, VicenteValero, DebuTripathy, SenthilkumarDamodaran, BanuKArun, JenniferKLitton, NaotoTUeno, RashmiKMurthy, BoraLim. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022. e-Pub 2022. PMID: 35507014.
Musall BC, Adrada BE, Valero V. Quantitative Apparent Diffusion Coefficients from Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Journal of Magnetic Resonance Imaging, 2022. e-Pub 2022.
ParvinFPeddi, PeterAFasching, DuanLiu, EmmanuelQuinaux, NicholasJRobert, VicenteValero, JohnCrown, CarlaFalkson, AdamBrufsky, JulieMCunningham, RichardMWeinshilboum, TadeuszPienkowski, WolfgangEiermann, MiguelMartín, ValerieBee, XiaoyanWang, LieweiWang, EricYang, DennisJSlamon, andSaraAHurvitz. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022. e-Pub 2022. PMID: 35110416.
Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220, 2022. e-Pub 2022. PMID: 35193025.
Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
ROSALINDPCANDELARIA, BEATRIZEADRADA, DEANNALLANE, GAIANEMRAUCH, STACYLMOULDER, ALASTAIRMTHOMPSON, ROLANDLBASSETT, ELSAMARRIBAS, HUONGTLE-PETROSS, JESSICAWTLEUNG, DAVIDASPAK, ELIZABETHERAVENBERG, JASONBWHITE, VICENTEVALERO. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound in Medicine, 2022. e-Pub 2022. PMID: 35300879.
Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer 8(1):18, 2022. e-Pub 2022. PMID: 35173164.
Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol 29 Suppl 1(Suppl 1):S35-S41, 2022. e-Pub 2022. PMID: 34272161.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Consortium IT, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23(1):149-160, 2022. e-Pub 2022. PMID: 34902335.
Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell 5:876100, 2022. e-Pub 2022. PMID: 36034598.
Yennurajalingam S, Valero V, Lu Z, Liu DD, Busaidy NL, Reuben JM, Diaz Fleming C, Williams JL, Hess KR, Basen-Engquist K, Bruera E. Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. J Natl Compr Canc Netw:1-9. e-Pub 2021. PMID: 34965510.
Zakon DB, Valero V. What is the best treatment recommendation for HER2+ IBC with residual disease?—a narrative review. Chinese Clinical Oncology, 2021. e-Pub 2021.
Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol 28(13):8610-8621, 2021. e-Pub 2021. PMID: 34125346.
Smetherman D, Biggs K, Fayanju OM, Grosskreutz S, Khan Z, Malak S, Moseley T, Smith-Graziani D, Valero V, Lightfoote J. Racial and Ethnic Disparities in Breast Cancer: A Collaboration Between the American College of Radiology Commissions on Women and Diversity and Breast Imaging. J Breast Imaging 3(6):712-720, 2021. e-Pub 2021. PMID: 38424936.
Smetherman D, Biggs K, Valero V. Racial and Ethnic Disparities in Breast Cancer: A Collaboration Between the American College of Radiology Commissions on Women and Diversity and Breast Imaging. Journal of Breast Imaging, 2021. e-Pub 2021.
Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. e-Pub 2021. PMID: 33878210.
Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol 28(8):4265-4274, 2021. e-Pub 2021. PMID: 33403525.
Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat 189(1):103-110, 2021. e-Pub 2021. PMID: 34120223.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol 39(21):2375-2385, 2021. e-Pub 2021. PMID: 34077270.
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol 39(20):2247-2256, 2021. e-Pub 2021. PMID: 33999652.
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol 32(5):642-651, 2021. e-Pub 2021. PMID: 33617937.
Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer 7(1):28, 2021. e-Pub 2021. PMID: 33742001.
Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2021. PMID: 33140515.
Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer 143:134-146, 2021. e-Pub 2021. PMID: 33307491.
Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel) 12(11), 2020. e-Pub 2020. PMID: 33114311.
Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg:e204103. e-Pub 2020. PMID: 33026457.
Bayraktar S, Baghaki S, Wu J, Liu DD, Gutierrez-Barrera AM, Bevers TB, Valero V, Sneige N, Arun BK. Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila) 13(9):795-802, 2020. e-Pub 2020. PMID: 32513785.
Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol 130:109170, 2020. e-Pub 2020. PMID: 32777736.
de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J 26(8):1572-1582, 2020. e-Pub 2020. PMID: 32497289.
Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Sinn BV, Layman R, Bedrosian I, Valero V, Symmans WF. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clin Chem 66(7):934-945, 2020. e-Pub 2020. PMID: 32613237.
Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist 25(6):e909-e919, 2020. e-Pub 2020. PMID: 32003919.
Grant SR, Krishnamurthy S, Le-Petross C, Valero V, Teshome M, Woodward WA. An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer. Breast J 26(5):1022-1024, 2020. e-Pub 2020. PMID: 31960546.
Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM, Ellis C, Ibrahim N, Yan L. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol 85(4):673-683, 2020. e-Pub 2020. PMID: 32062691.
Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care 10(1):25-35, 2020. e-Pub 2020. PMID: 30244203.
Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38(5):388-394, 2020. e-Pub 2020. PMID: 31461380.
Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. e-Pub 2017. PMID: 29197959.
Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. e-Pub 2017. PMID: 29064904.
Candelaria RP, Hansakul P, Thompson AM, Le-Petross H, Valero V, Bassett R, Huang ML, Santiago L, Adrada BE. Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. Am J Surg. e-Pub 2017. PMID: 28712671.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. e-Pub 2017. PMID: 28549010.
Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. e-Pub 2017. PMID: 28423171.
Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. e-Pub 2017. PMID: 28199747.
Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ. Molecular profiling using breast cancer subtype to plan for breast reconstruction. Plast Reconstr Surg. e-Pub 2016. PMID: 27893626.
Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. e-Pub 2016. PMID: 27573653.
Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. e-Pub 2016. PMID: 27374101.
Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. e-Pub 2016. PMID: 27298406.
Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo A, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1):58. e-Pub 2014. PMID: 25051981.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchyman Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther 11(11). e-Pub 2012. PMID: 22973057.
Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. The Oncologist 16(12):1675-83. e-Pub 2011. PMID: 22147002.
Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 29(32):4286-93. e-Pub 2011. PMID: 21990397.
Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. J Clin Oncol 29(28):3739-46. e-Pub 2011. PMID: 21900106.
Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J. e-Pub 2011. PMID: 21726347.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67. e-Pub 2011. PMID: 21699723.
Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. e-Pub 2010. PMID: 21117228.
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in ER-positive and -negative cancers. J Clin Oncol 28(28):4316-23. e-Pub 2010. PMID: 20805453.
Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77. e-Pub 2010. PMID: 20564153.
Esteva FJ, Wang J, Feng L, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9. e-Pub 2007. PMID: 18086299.
Valero V, Kuerer H. Longitudinal Patient-Reported Outcomes in a Phase 2 Cancer Clinical Trial of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy. JAMA.
A Fasching DP, Liu DD, Quinaux DE, Robert DN, Valero DV, Crown DJ, Falkson DC, M Brufsky DA, M Cunningham DJ, M Weinshilboum DR, Pienkowski DT, Eiermann DW, Martín DM, Bee MV, Wang X, Wang L, H Yang DE, Slamon DJ, A Hurvitz DS. Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients. Clinical Cancer Research.
Hennessy B, Ju Z, Agarwal R, Carey M, Lluch A, Myhre S, J-S L, Gonzalez-Angulo AM, Coombes KR, Broaddus R, Sahin AA, Valero V, A-L B, Mills GB. Proteomic predictors of outcome after adjuvant anti-hormonal therapy for hormone receptor-positive breast cancer. J Clin Onc.
Murthy RK, Varma A, Mishra P, Hess KR, C-Y Y, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Trastuzumab-Naive Patients with HER2 Positive Metastatic Breast Cancer have Superiod Clinic Outcomes to Trastuzumab-Based Therapy in the Metastatic Setting. J Clin Onc.

Editorials

Chavez MacGregor M, Valero V. Commentary on: Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative interentional cohort study of 13722 women. Breast Diseases: A Year Book Quarterly.

Abstracts

Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. e-Pub 2010.
Valero V, Mouabbi J, Alonzo H, Ilheme A, Murthy R, Huang X, Qiao W, Patel M, Pohlmann P, Rauch G, Checka C, Hunt K, Tripathy D, Meric-Bernstam F, Symmans F. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer.
Dieras V, Yardley DA, Romieu G, Valero V, Isakoff S, Thurm H, Teng SL, Campone M. A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC). 2013 SABCS.
Kogawa T, Fouad T, Liu DD, Shen Y, Kai K, Chavez Mac Gregor M, Alvarez RH, Valero V, Hortobagyi GN, Ueno NT. Stage-matched comparison of neoadjuvant systemic chemotherapy with trastuzumab in HER2+ primary inflammatory breast cancer and HER2+ non-inflammatory locally advanced breast cancer.
Kogawa T, Fouad T, Liu DD, Shen Y, Masuda H, Chavez Mac Gregor M, Alvarez RH, Valero V, Hortobagyi GN, Ueno NT. Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer.
Ueno NT, Jackson SA, Alvarez RH, Willey JS, Hortobagyi GN, Angulo-Gonzalez AM, Giordano SH, Booser DJ, Valero V. Preliminary report of a phase I/II study of entinostat (IND#NSC 706995, /M275) and lapatinib (IND#NSC 727989) in patients with HER2-positive metastatic breast cancer in whom trastuzumab has failed. 2012 SABCS.
Chavez Mac Gregor M, Lei X, Giordano SH, Valero V, Esteva F, Mittendorf EA, Gonzalez-Angulo AM, Hortobagyi GN. Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC). 2012 SABCS.
Conter HJ, Conter D, Wolff RA, Valero V, Zwelling L. The benefit of targeted therapeutics in medical oncology since the development of trastuzumab. 2012 SBACS.
Anfossi S, Giordano A, Cohen EN, Gao H, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, B-N L, Cristofanilli M, Reuben JM. High serum levels of miR-19a are associated with poor outcome in metastatic inflammatory breast cancer. 2012 SABCS.
Willey JS, Alvarez RH, Valero V, Lara JM, Parker CA, Hortobagyi GN, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin for patients with primary inflammatory breast cancer (IBC) without HER2 overexpression. 2012 SABCS.
Masuda H, Iwamoto T, Brewer T, Hsu L, Kai K, Woodward WA, Reuben JM, Valero V, Alvarez RH, Willey J, Hortobagyi GN, Ueno NT. Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression. 2012 SABCS.
B-N L, Arun BK, Cohen EN, Tin S, Gutierrez-Barrera AM, Miura T, Kiyokawa I, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM. Sialyl LewisX and inflammatory mediators in breast cancer patients: biological correlations and prognostic value. SABCS.
Murthy RK, Mishra P, Varma A, Hess KR, Young C, Murray JL, Koenig KB, Green MC, Moulder SL, Melhem-Bertrandt A, Booser D, Valero V, Hortobagyi GN, Esteve FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2 targeted therapy in the metastatic setting. ASCO 2012 Annual Meeting.
Brufsky AM, Hurvitz S, Perez E, Yamamoto H, Valero V, O'Neill V, Rugo HS. Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) vs placebo (PL) combined with 2nd-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). 2012 Breast Cancer Symposium.
Brufsky AM, Hurvitz S, Perez E, Yamamoto H, Valero V, O'Neill V, Rugo HS. Final analysis of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) vs placebo (PL) combined with 2nd-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). ASCO 2012 Annual Meeting.
Giordano A, Barnato SE, Giuliano M, Alvarez RH, Cristofanilli M, Hortobagyi GN, Valero V, Reuben J. Effect of targeted therapy on circulating tumor cells in metastatic breast cancer patients. ASCO 2012 Annual Meeting.
De Giorgi U, Mego M, Scarpi E, Handy BC, Jackson SA, Reuben J, Valero V, Hortobagyi GN, Ueno N, Cristofanilli M. Relationship between lymphopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 35th European Society for Medical Oncology (ESMO) Congress 21(8):67-67.

Less

Selected Presentations & Talks

Local Presentations

2013. Systemic Management of Early and Advanced Triple Negative Breast Cancer. Conference. UTMDACC. Houston, TX, US.
2012. Treatment of Early Stage Breast Cancer. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2012. Cancer de mama, preguntas y temas relacionados. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2010. Systemic Treatment of HER2-Normal Metastatic Breast Cancer. Conference. PREX. Houston, TX, US.
2009. Speaking of Your Health Lecture - Breast Cancer Basics: A Candid Talk About Diagnosis, Research and Treatment. Conference. The Harris County Hospital District Foundation. Houston, TX, US.
2009. Utilizing the RS to Complement the Path Report. Conference. Park Plaza Hospital and Medical Center. Houston, TX, US.
2008. Management of anthracycline taxane-resistant and anthracycline taxane-capecitabine-resistant metastatic breast cancer: New options Ixabepilone. Conference. Memorial City for Oncology Consultants. Houston, TX, US.
2008. Breast Cancer and Health Disparities. Conference. MDACC. Houston, TX, US.
2008. Special Considerations in Vulnerable Populations. Conference. University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2008. Health Issues for Hispanics in the Greater Houston Area. Conference. Institute of Hispanic Culture. Houston, TX, US.
2007. Managing Metastatic Breast Cancer: Present and New Treatment Options. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2007. Las Rosas Vivas. Conference. Hispanic Breast Cancer Survirors Support Group. Houston, TX, US.
2007. Advances in biologic therapies and novel agents for breast cancer. Conference. Physicians' Education Resource. Houston, TX, US.
2007. Overview of outreach efforts related to clinical services. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2006. The evolving role of HER2-targeted therapies in breast cancer. Conference. Kelsey-Seybold. Houston, TX, US.
2005. Incorporating genomics into the management of breast cancer. Conference. West Houston Medical Center. Houston, TX, US.
2005. The evolving role of HER2-targeted therapies in breast cancer. Conference. Kelsey-Seybold. Houston, TX, US.
2005. Adjuvant hormone therapy for postmenopausal women: can we come to consensus?. Conference. University of North Texas Health Science Center. Houston, TX, US.
2005. Trastuzumab as adjuvant therapy. Conference. University of North Texas Health Science Center. Houston, TX, US.
2005. New treatments for metastatic breast cancer: are they for you?. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2004. Management of metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2004. Multidisciplinary systemic treatment of breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2004. A post-SABCS update on the management of breast cancer. Conference. Oncology Consultants. Houston, TX, US.
2004. Adjuvant and neoadjuvant chemotherapy for early breast cancer and large operable breast cancer. Conference. West Houston Medical Center. Houston, TX, US.
2003. Breast Cancer Chair. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2003. Management of metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2003. ASCO 2003 Breast Cancer Review. Conference. Twelve Oaks Hospital. Houston, TX, US.
2003. Epidermal GFR inhibition—a clinical reality: Overview of current agents and MDACC current protocols. Conference. The University of Texas M. D. Anderson Cancer Center, Department of Breast Medical Oncology. Houston, TX, US.
2003. Chemotherapy for metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2002. Update on clinical trials and advances in The Department of Breast Medical Oncology. Conference. The University of Texas M. D. Anderson Alumni and. Houston, TX, US.
2002. Breast Cancer Chair. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2002. Management of metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2002. Adjuvant therapy and the role of taxanes in the treatment of breast cancer. Conference. Twelve Oaks Medical Center. Houston, TX, US.
2001. Management of metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2001. Breast Cancer Chair. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2000. Locally advanced, inflammatory and metastatic disease. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1999. New agents in the management of metastatic breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1999. Reducing the incidence of breast cancer in women with high risk. Conference. Memorial Northwest Hospital. Houston, TX, US.
1997. Breast cancer prevention. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2013. Systemic Management of Early and Advanced Triple Negative Breast Cancer. Conference. UTMDACC. Hosuton, TX, US.
2013. Management of Breast Cancer: New Options in 2013. Conference. Doctors Hospital at Renaissance. Edinburg, TX, US.
2012. Maximizing Benefits; Minimizing Risks in Metastatic Breast Cancer. Conference. Prime One Twelve. Miami Beach, FL, US.
2012. Spotlight on Recurrent Metastatic Breast Cancer. Conference. Hoag Medical Center. Newport Beach, CA, US.
2012. Spotlight on Recurrent Metastatic Breast Cancer. Conference. Inova Alexandria Hopsital. Alexandria, VA, US.
2012. Spotlight on Recurrent Metastatic Breast Cancer. Conference. University of Missouri. Columbia, MO, US.
2011. Management of Advanced and Early HER2 Amplified Breast Cancer – Current and Future Direction. Conference. Smilow Cancer Hospital. New Haven, CT, US.
2011. Cancer de Mama, Preguntas y Temas Relacionados. Conference. UT MD Anderson Cancer Center. Katy, TX, US.
2011. HER2+ Breast Cancer Management: Practical Strategies for Everyday Use. Conference. Holmes Regional Medical Center. Melbourne, FL, US.
2011. Management of Metastatic Breast Cancer Combinatinos versus Single Agent. Conference. University of Miamai. New Orleans, LA, US.
2010. State of Art Breast Cancer Care - The Next Decade of Novel Therapies. Conference. Texas Oncology Group. Austin, TX, US.
2010. Novel Development in the treatment of metastatic breast cancer. Conference. 5th Annual Cancer Meeting. New Orleans, LA, US.
2010. Update on Primary Systemic, Hormonal, Biological and Chemotherapy. Who and Which Therapy?. Conference. Doctors Hospital at Renaissance. McAllen, TX, US.
2009. Individualizing Adjuvant Therapy for Early Breast Cancer: Pharmacogenomics as Emerging Diagnostic and Molecular Diagnostics Tool for Risk Stratification and Treatment Individualization. Conference. Texas Oncology. McAllen, TX, US.
2008. Breast Cancer Management: Updates, Advances and New Options. Conference. UT Health Science Center of San Antonio. San Antonio, TX, US.
2007. Utilizing Genomics in Early-Stage Breast Cancer. Conference. UTMB. Galveston, TX, US.
2007. Utilizing Genomics in Early-Stage Breast Cancer. Conference. UTMB Grand Rounds. Galveston, TX, US.
2007. Molecular diagnostics for Risk Assessment and Treatment Individualization. Conference. Physicians' Education Resource. Dallas, TX, US.
2007. HER2 Targeting Agents in Clinical Practice Improving Patient Outcomes from Early to Advanced Breast Cancer. Conference. Mercy Regional Cancer Center. Laredo, TX, US.
2007. Adjuvant and metastatic breast cancer. Conference. Methodist Hospital. Dallas, TX, US.
2007. Utilizing genomics in early-stage breast cancer. Conference. Bayshore Medical Center. Pasadena, TX, US.
2006. Integrating novel therapies into the treatment of breast cancer. Conference. Christus St. Patrick Hospital. Lake Charles, LA, US.
2006. Improving the therapeutic index of adjuvant systemic therapy in ER-postive node-negative breast cancer. Conference. Christus Spohn Hospital. Corpus Christi, TX, US.
2006. Chemotherapy 101 for surgeons. Conference. Providence Saint Joseph Medical Center. Burbank, CA, US.
2006. The evolving role of HER2-targeted therapies in breast cancer. Conference. Glendale Adventist Medical Center. Glendale, CA, US.
2006. Update on the treatment of early breast cancer. Conference. Kaiser Cancer Unit. Santa Monica, CA, US.
2006. New innovative treatments in breast cancer. Conference. Covenant Health System. Lubbock, TX, US.
2006. The evolving role of HER2-targeted therapies in breast cancer. Conference. South Miami Hospital. Miami, FL, US.
2006. Does dose-dense make sense?. Conference. Baptist Hospital. Pensacola, FL, US.
2005. Does dose-dense make sense?. Conference. University of North Texas Health Science Center. Fort Worth, TX, US.
2005. The evolving role of HER2-targeted therapies in breast cancer. Conference. St. Paul University Hospital. Dallas, TX, US.
2005. The evolving role of HER2-targeted therapies in breast cancer. Conference. St. Paul Medical Center. Dallas, TX, US.
2005. Breast cancer update for primary care. Conference. Texas Medical Association. South Padre Island, US.
2005. Update on targeted therapies in the treatment of breast cancer. Conference. Medical Center of Plano. Plano, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. The University of Texas Medical Branch. Galveston, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Spohn Hospital. Corpus Christi, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Baylor Medical Center. Garland, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Baylor Health Center. Irving, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Harrington Cancer Center. Amarillo, TX, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Joe Arrington Cancer Center. Lubbock, TX, US.
2003. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Conference. Laredo Mercy Hospital. Laredo, TX, US.
2003. ASCO update on breast cancer. Conference. Aventura Cancer Center. Miami, TX, US.
2003. Breast cancer treatments. Conference. Cleo Craig Memorial Cancer & Research Clinic. Lawton, TX, US.
2003. EGFR/Her2 in breast/ovarian cancer, CME program, Understanding the Human Epidermal Growth Factor Receptor (HER) Signal Transduction Pathway for Treating Solid Tumors. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, OK, US.
2003. Highlights of the 39th Annual Meeting of ASCO. Conference. The University of Texas Medical Branch. Galveston, FL, US.
2003. Highlights of the 39th Annual Meeting of ASCO. Conference. The University of Texas Medical Branch. Galveston, TX, US.
2003. Post-ASCO update on treatment of metastatic breast cancer. Conference. University of Texas Medical Branch. Beaumont, TX, US.
2003. Post-ASCO highlights in treatment of metastatic breast cancer. Conference. The University of Texas Medical Branch. Clear Lake, TX, US.
2003. Highlights of the 2002 San Antonio Breast Cancer Symposium. Conference. McAllen Medical Center. McAllen, TX, US.
2003. New options in the adjuvant treatment of early-stage breast cancer. Conference. Gulf Coast Medical Center. Wharton, US.
2003. New options in the adjuvant treatment of early-stage breast cancer. Conference. The University of Texas Medical Branch at Galvesto. San Antonio, TX, US.
2003. The role of platinum in metastatic breast cancer. Conference. The Texas A & M University System Health Science Center. Corpus Christi, TX, US.
2003. Adjuvant therapy in early breast cancer. Conference. Kelsey-Seybold Clinic. Houston, MA, US.
2003. Advances in Strategies for early-stage breast cancer. Conference. Manchester Memorial Hospital. Manchester, CT, US.
2003. Adjuvant therapy in early breast cancer. Conference. MidState Medical Center. Meriden, TX, US.
2003. Update on advances in metastatic breast cancer. Conference. Spring Branch Medical Center. Spring Branch, TX, US.
2002. Advances in the treatment of metastatic breast cancer. Conference. The University of Texas Medical Branch. Galveston, TX, US.
2000. The primary and secondary prevention of breast cancer. Conference. Valley Regional Medical Center. Brownsville, TX, US.
2000. Advancements in breast cancer. Conference. Memorial Hermann Baptist, Julie & Ben Rogers Cancer Institute. Beaumont, TX, US.
1999. Current prospective and future directions regarding the roles of bisphosphonate therapy in breast cancer. Conference. Spohn Hospital. Corpus Christi, TX, US.
1999. Advances in the treatment of metastatic breast cancer. Conference. Clear Lake Hospital. Clear Lake, TX, US.
1999. Reducing the incidence of breast cancer with tamoxifen in women with high risk. Conference. Brownsville Medical Center. Brownsville, TX, US.
1999. Advances in the treatment of metastatic breast cancer. Conference. Citizen's Medical Center. Victoria, TX, US.
1998. Reducing the incidence of breast cancer with Nolvadex (tamoxifen) in women with high risk. Conference. Sadler Clinic. Conroe, TX, US.
1998. Breast cancer. Conference. Columbia Valley Regional Medical Center. Brownsville, TX, US.
1998. Advances in the treatment of anthracycline-resistant metastatic breast cancer. Conference. McAllen Cancer Center. McAllen, TX, US.
1998. Advances in the treatment of breast cancer. Conference. The Methodist Hospital. Lubbock, TX, US.
1996. Taxotere/Taxol--advantages in breast cancer. Conference. The University of Texas Southwestern Medical School. Dallas, TX, US.

National Presentations

2023. Neoadjuvant Therapy. Conference. AARC. Maui, HI, US.
2022. Best of Asco. Conference. Best of Asco. Mexico City, US.
2014. Recurrent HER-2 Breast Cancer: Beyond Trastuzimab. Invited. UTMDACC 12th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2013. Novel Developments for Systemic Therapy in Breast Cancer Including HER-2 Blockage (Non-Hormonal Therapies). Invited. 3rd Annual Puerto Rico Fall Cancer Symposium. San Juan, Puerto Rico, US.
2013. Novel Approaches for Metastatic Hormonal Resistent Breast Cancer Patients. Invited. 8th Annual New Orleans Summer Cancer Meeting. New Orleans, LA, US.
2013. Multiagent targeting in the treatment of HER-2 Positive breast cancer. Invited. 11th Oncology Update: Advances and Controversies Conference. Houston, TX, US.
2012. Berast Cancer: Updates in non-HER2 and HER2 breast cancer management. Invited. 2nd Las Vegas Fall Cancer Symposium 2012. Las Vegas, NV, US.
2011. Novel Combinations in the Treatment of Metastatic Breast Cancer. Invited. The Medical Educator Consortium. Las Vegas, NV, US.
2010. Personalizing Adjuvant Therapy in Breast Cancer Treatment. Invited. MD Anderson Cancer Center. New York, NY, US.
2009. Neoadjuvant / Metastatic Therapies. Invited. Post SABCS Review. Pittsburg, PA, US.
2009. Targeted Therapy in Breast Cancer Patients: Integration of Trastuzumab and Bevacizumab in Clinical Practice. Invited. 9th Annual Oncology Symposium. Park City, UT, US.
2008. Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2008. Early Breast Cancer Management: Updates, Advances and New Options 2008. Invited. Texas Society of Medical Oncology. Fort Worth, TX, US.
2008. Development and Integration of Treatment Strategies in Breast Cancer. Invited. Breast Cancer Management: Updates, Advances and New Options. Topeka, KS, US.
2008. Evolving Insights into Molecular Subtypes. Invited. Current Trends in Breast Cancer. San Juan, PR, US.
2008. Optimizing Management of Advanced Breast Cancer. Invited. Review and Interpretations of the 2007 SABCS. Tampa, FL, US.
2007. IGF1R and Pan HER Inhibitors (Breakout discussion). Invited. 4th Annual Breast Cancer Think Tank. New York, NY, US.
2007. Breast Committee, Breast Committee Working Group, and Foundation Research Program Steering Committee. Invited. National Survical Adjuvant Breast and Bowel Project (NSABP), Group Meeting. Jacksonville, FL, US.
2007. Emerging biological treatments for breast cancer. Invited. Review and Interpretations of the 2006 SABCS. Tampa, FL, US.
2007. Treatment of post-menopausal ER+ patient--Is hormone therapy alone adequate treatment?. Invited. 7th Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2006. Breast Committee Meeting and Breast Committee Working Group Meeting. Invited. National Surgical Adjuvant Breast and Bowel Project (NSABP), Group Meeting. Denver, CO, US.
2006. Dosing issues in systemic therapy: Fulvestrant (loading vwersus standard dose), capecitabine alone or in combination (lower versus standard dose). Invited. Optimal Management of Early and Metastatic reast Cancer--a Case-Based Roundtable Discussion, Meet the Professors. Bal Harbour, FL, US.
2006. Recent advances in adjuvant therapy in early breast cancer. Invited. 6th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
2005. Avances en el diagnostico y tratamiento multidisciplinario del cancer de mama nuevos conceptos. Invited. University of Puerto Rico Cancer Center Seminar Series. San Juan, PR, US.
2005. Current status of adjuvant Herceptin therapy. Invited. 5th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
2004. Locally advanced breast cancer. Invited. 2004 School of Breast Oncology. Atlanta, GA, US.
2004. National Surgical Adjuvant Breast and Bowel Project (NSABP). Invited. Fall Meeting, Breast Committee Meeting and Breast Committee Working Group Meeting. Huntington Beach, CA, US.
2004. Primary (neoadjuvant) systemic therapy for breast cancer: A review of current trials. Invited. 10th Annual Perspectives in Breast Cancer. Boston, MA, US.
2004. Evolving role of adjuvant Herceptin therapy. Invited. 4th Annual Oncology Update: Advances and Controversies. Steamboat Springs, US.
2004. Advances in breast cancer treatment: the Hispanic patient. Invited. Hispanic Breast Cancer Conference. Miami, FL, US.
2004. New approaches in stage IV disease. Invited. 4th Annual Oncology Update: Advances and Controversies. Steamboat Springs, US.
2003. Locally advanced breast cancer. Invited. School of Breast Oncology, Emory University Conference Center. Atlanta, GA, US.
2003. Systemic adjuvant therapy in early breast cancer. Invited. 7th Annual Cincinnati Comprehensive Breast Cancer Conference, Charting a Course for Advanced Breast Cancer. Cincinnati, OH, US.
2003. Systemic therapy for metastatic breast cancer. Invited. 3rd Annual Karmanos Cancer Institute Breast Cancer Symposium. Dearborn, MI, US.
2003. Systemic Therapy for Metastatic Breast Cancer. Invited. 3rd Annual Karmanos Cancer Institute Breast Cancer Symposium: A Multi-Disciplinary Approach. Dearborn, MI, US.
2003. New agents in the adjuvant and neoadjuvant treatment of early breast cancer. Invited. 14th Alabama Cancer Congress. Destin, FL, US.
2003. New agents in the adjuvant and neoadjuvant treatment of early breast cancer. Invited. 14th Alabama Cancer Congress. Destin, FL, US.
2003. Advances in adjuvant treatment for breast cancer. Invited. Future Directions in Hematology and Oncology. Sea Island, GA, US.
2003. ASCO breast cancer update. Invited. Quarterly Forum on Breast Cancer Issues. Davie, FL, US.
2003. Novel anti-cancer agents in development. Invited. 21st Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2003. Primary chemotherapy in operable and locally advanced breast cancer: the M. D. Anderson experience. Invited. 20th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2002. Advances in the treatment of breast cancer. Invited. 4th Annual Cancer Congress. Savannah, GA, US.
2002. Adjuvant treatment in early breast cancer: overview and controversies. Invited. 7th Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2001. Cancer de mama en etapas tempranas. Invited. The University of Texas M. D. Anderson Cancer Center Conferencia Internacional de Hemato-Oncologia Medica. Houston, TX, US.
2000. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- tamoxifen in locally advanced breast cancer. Invited. 23rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
1997. Taxotere in metastatic breast cancer. Invited. National Meeting of San Juan CCOP. San Juan, PR, US.
1995. Docetaxel (Taxotere) therapy in paclitaxel-resistant metastatic breast cancer (poster presentation). Invited. 18th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
1994. Liposomal doxorubicin, 5-FU and cyclophosphamide in metastatic breast cancer. Invited. Chemotherapy Foundation Symposium XII. New York, NY, US.

International Presentations

2023. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer. Invited. Zymeworks. BERLIN, DE.
2013. Negative Hormonal Resistant Metastatic Breast Cancer: Current Options and Future Directions. Invited. InterAmerican Oncology Conference. Buenos Aires, AR.
2013. Primary and adjuvant systemic therapy in patients with HER2 normal/ER positive and Triple Receptor Negative Early and Locally Advanced Breast Cancer. Invited. University of Buenos Aires. Buenos Aires, AR.
2013. Management of HER2 normal ER positive Metastatic Breast Cancer: New Options. Invited. University of Buenos Aires. Buenos Aires, AR.
2013. Triple Negative/Cytotoxics Breast Cancer ASCO Abstract Presentations. Invited. Best of ASCO Panama. Panama City, PA.
2013. HER2/ER Breast Cancer ASCO Abstract Presentations. Invited. Best of ASCO Panama. Panama City, PA.
2013. Breast Cancer ASCO Abstract Discussions. Invited. Best of ASCO Cancun. Cancun, MX.
2013. Hormone resistance: options for the inevitable Neuvas. Invited. GEICAM IV International Symposium. Valencia, ES.
2012. Hormonal Treatment. Invited. Summit Oncology Experts Reunion. Bariloche, AR.
2012. Cancer de Mama - Clinica e Investigacion. Invited. Congreso Integrado de Sociedades de Oncologia. Lima, PE.
2012. Herceptin-induced Cardiotoxicity. Invited. 2nd International Conference on Cancer and the Heart. Houston, US.
2012. Management of Advanced and Early HER2 Amplified Breast Cancer. Invited. Sociedad Peruana de Oncologia Medica. Lima, PE.
2012. Breast cancer updates. Invited. Best of ASCO. Cancun, MX.
2012. Treating HER2-Positive Breast Cancer. Invited. University of Miami. Cancun, MX.
2012. Assessing Recurrence Risk and the 2012 Standard of Care for Adjuvant Chemotherapy. Invited. University of Miami. Cancun, MX.
2012. Best of ASCO Breast Cancer. Invited. ASCO, PA.
2012. Adjuvant Chemotherapy in Early Breast Cancer. Invited. DCIS and Early Breast Cancer Symposium with International Contributions. Cappadocia, TR.
2012. DCIS and Systemic Therapy. Invited. DCIS and Early Breast Cancer Symposium with International Contributions. Cappadocia, TR.
2012. Breast Cancer Overview. Invited. INTERNATIONAL ANNUAL MEETING OF INTERNAL MEDICINE. Saltillo, MX.
2012. Roundtable Stage Breast Cancer. Invited. XXXI Venezuelan Congress of Surgery, VE.
2011. New Treatment for Triple Negative Breast Cancer. Invited. United States-Latin America Cancer Research Network. Guadalajara, MX.
2011. Personalized Therapy in Breast Cancer. Invited. MD Anderson Cancer Center's experience and vision of future cancer treatment: The challenge of personalized medicine. Madrid, ES.
2011. Breast Cancer - HER2/ER/Triple Negative. Invited. Best of ASCO. Cancun, MX.
2011. Triple Negative/Cytotoxics/Local Therapy. Invited. Best of ASCO. Lima, PE.
2011. Breast Cancer - Triple Negative/Cytotoxics/Local Therapy. Invited. 2011 Best of ASCO. Salinas, EC.
2011. Breast Cancer - ER/HER2+. Invited. 2011 Best of ASCO. Salinas, EC.
2011. Treatment of Metastatic HER-2 Positive Breast Cancer. Conference. Breast Cancer Conference. Sao Paulo, BR.
2011. Genetic Profile for Adjuvant Treatment Selection. Invited. Breast Cancer Conference. Sao Paulo, BR.
2011. Adjuvant Chemotherapy for HER-2 Positive Breast Cancer of Less than 1cm. Invited. Breast Cancer Conference. Sao Paulo, BR.
2010. Uso óptimo de los Inhibidores de la aromatasa (Sesión Educacional). Invited. 3rd International Oncology Congress. Cordoba, AR.
2010. Integración de nuevos fármacos en el tratamiento del cáncer mama avanzado. Invited. 3rd International Oncology Congress. Cordoba, AR.
2010. Farmacogenomica y Cáncer de Mama. Invited. 3rd International Oncology Congress. Cordoba, AR.
2010. Metastatic Breast Cancer. Invited. Best of ASCO Annual Meeting. Cancun, MX.
2010. Controversies on the use of anthracyclines in early breast cancer. Invited. VII Peruvian Congress of Medical Oncology. Cuzco, PE.
2010. Optimal treatment for triple negative breast cancer. Invited. VII Peruvian Congress of Medical Oncology. Cuzco, PE.
2010. Management of Metastatic Breast Cancer HER2/neu + and Triple Negative Receptors. Invited. Association of Hematology and Oncology. Antigua, GT.
2010. NeoAdjuvant Therapy in Breast Cancer, Which is the Best Choice. Invited. Association of Hematology and Oncology. Antigua, GT.
2010. Early Breast Cancer and Its Treatment. Invited. Association of Hematology and Oncology. Antigua, GT.
2010. The strategies of HER-2 negative metastatic breast cancer treatment (First-line and salvage therapy). Invited. 4th Chinese Conference on Medical Oncology (CCMO). Beijing, CN.
2010. Adjuvant Chemotherapy: Assessing Recurrence Risk and Defining the Standard of Care for 2011. Invited. 5th Inter-American Breast Cancer Conference. Cancun, MX.
2010. Incidence and Treatment Practices in Breast Cancer: the Latin America Experience. Invited. 5th Inter-American Breast Cancer Conference. Cancun, MX.
2010. Latin American Medical Eductaion Program in Gene Expressing Profiling for Early Stage Breast Cancer. Invited. Latin American Medical Eductaion Program in Gene Expressing Profiling for Early Stage Breast Cancer. Cancun, MX.
2010. Future in the diagnosis and treatment of breast cancer. Invited. INTERMeeting agency. Manzanillo, MX.
2009. Project LEAD. Invited. National Breast Cancer Coalition (NBCC). Buenos Aires, AR.
2009. Is personalized adjuvant systemic therapy ready for prime time? Multigene platforms or signatures, Oncotype-DX, Mammaprint, Rotterdam signatures. Invited. 2nd Latin American Congress. Cancun, MX.
2009. International Symposium on Breast Cancer - ROLE OF CHEMOTHERAPY IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER. Invited. Board of the Peruvian Society of Medical Oncology. Lima, PE.
2009. ‘Review on targeted therapy in advanced and early breast cancer’ and ‘Primary systemic therapy (neoadjuvant) in large operable and locally advanced breast cancer’. Invited. Breast Cancer Leadership Program. Dubai, EG.
2009. New prognostic and predictive factors in ErbB2 positive breast cancer. Invited. Mexican Society of Oncologic Studies (SMeO) National Congress. Acapulco, MX.
2009. New Drugs in Breast Cancer. Invited. III InterAmerican Oncology Conference. Buenos Aires, AR.
2009. Is personalized adjuvant systemic therapy ready for prime time? Multigene platforms or signatures, Oncotpe DX, Mamaprint, Rotterdam signatures. Invited. Multidisciplinary Management of Breast Cancer, PA.
2009. Breast Cancer - Local/Regional and Adjuvant therapy, Metastatic and New Drug Therapies. Invited. The Best of ASCO 2009. Cancun, MX.
2009. Therapies in Breast Cancer. Invited. The Best of ASCO 2009. Cancun, MX.
2009. Quimioterapia Neoadyuvante en Cancer de Mama. Invited. Hospital de Oncologia Centro Medico Nacional Siglo XXI. Guadalajara, MX.
2009. Nuevos desafios en el tratamiento del cancer de mama metastasico. Invited. Breast Cancer Symposium 2009. Mendoza, AR.
2009. Breast Cancer: Local/Regional and Adjuvant Therapy. Invited. Best of ASCO 2009. Panama City, PA.
2009. Adjuvant chemotherapy in HER-2 negative breast cancer. Invited. Breast Cancer International Symposium. Sao Paulo, BR.
2009. Neoadjuvant and adjuvant treatment of HER-2 negative breast cancer management of metastatic HER-2 negative breast cancer. Invited. Hospital Albert Einstein. Sao Paulo, BR.
2009. Current Challenges in the Multidisciplinary Approach to Neoadjuvant Therapy of Breast Cancer. Invited. ASCO Annual Meeting. Orlando, US.
2009. Gene Expression Profiling with Oncotype DX. Invited. International Symposium on Breast Cancer. Sao Paulo, BR.
2008. Neoadjuvant therapy, Hormonal and Biological therapy. Who and which therapy?. Invited. Multidisciplinary Management of Breast Cancer. Madrid, ES.
2008. Is personalized adjuvant systemic therapy ready for prime time? Multigene platforms or signatures, Oncotype-DX, Mammaprint, Rotterdam signatures. Invited. Multidisciplinary Management of Breast Cancer. Madrid, ES.
2008. Los Ultimos Datos Clinicos de Lapitinib. Invited. El Cancer de Mama Erb-B2 Positivo. Leon, MX.
2008. Avances Recientes en el Tratamiento de Mama Metastatico. Invited. El Cancer de Mama ERB-B2 positivo. Leon, MX.
2008. Lapatinib Indications: Present and Future Regimes. Invited. Best of ASCO - External Expert Meeting. Cancun, MX.
2008. Hormone Therapy in the Adjuvant Breast Cancer. Invited. Congress & International Meeting of the Mexican Association of Breast Diseases. Veracruz, MX.
2008. Breast Health Global Initiative: 2007 Summit and Guidelines and Overview of Adjuvant Chemotheraphy: Assessing Risk and Defining Standard of Care in 2008. Invited. 4th Inter-American Breast Cancer Conference (IABCC). Cancun, MX.
2008. Features with prolonged use aromatase inhibitors in breast cancer. Invited. III Congresso International / V Congresso National / VIII Reunion De Oncologist Society. Guatemala City, GT.
2008. Low Rick EBC Patient. Invited. First Latin American Oncology Summit. Buenos Aires, AR.
2008. Moelecular Target Therapy. Invited. 3rd International Congress. Puebla, MX.
2008. Advuvant Online: Value and Cristicism. Invited. 17th Annual Cairo University Conference. Ain Soukhna, EG.
2008. Chemotherapy and therapies targeted at breast cancer. Invited. Instituto Nacional de Cancerologia de Mexico (INCAN). San Luis, MX.
2008. Neoadjuvant Updates - The Future of Breast Cancer Treatment. Invited. Mexican Society of Cancer Breast Cancer Consensus. Colima, MX.
2007. Neoadjavant Treatment. Invited. XVIII Congreso Argentino De Oncologia Clinica. Rosario, AR.
2007. Antiangiogenic Therapy should be considered as the base of treatment?. Invited. Congresso de la Sociedad Mexicana de Estudios Oncologicos. Mexico City, MX.
2007. Panoramica de los Problemas Universales de la Salud. Invited. Forum de las Culturas 2007. Monterrey, MX.
2007. Curso de cirugia oncoplastica (panel discussion). Invited. XIV Congreso Latinoamericano de Mastologia. Cusco, PE.
2007. Comprendiendo la resistencia (Plenaria). Conference. XIV Congreso Latinoamericano de Mastologia. Cusco, PE.
2007. Cancer de mama triple negativo. Conference. XIV Congreso Latinoamericano de Mastologia. Cusco, PE.
2007. Inhibidores de tirosin kinasa en cancer de mama. Invited. XIV Congreso Latinoamericano de Mastologia. Cusco, PE.
2007. 4 ASCO abstracts. Breast Cancer session. Invited. Best of ASCO. Panama City, PA.
2007. BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. Invited. American Society of Clinical Oncology 43rd Annual Meeting. Chicago, US.
2007. BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. Invited. 2007 ASCO Annual Meeting, US.
2007. Tratamiento quimioterapico de las pacientes HER-negativo RE+. Invited. VI Simposio Internacional del GEICAM. Seville, ES.
2007. Conferencia magistral: Estado del arte en hormonoterapia para cancer de mama. Invited. XXIV Reunion Annual Medica del Instituto Nacional de Cancerologia (INCAN). Mexico City, MX.
2006. Update on adjuvant and neoadjuvant therapy of HER2-overexpressing early breast cancer. Invited. 16th Annual Conference. Cairo, EG.
2006. Pharmacogenomics: Emerging diagnostic test to predict disease relapse and benefit to adjuvant and primary systemic therapy in patients with breast cancer. Invited. 16th Annual Conference. Cairo, EG.
2006. Survival impact of local and systemic treatment in metastatic breast cancer patients. Invited. Expert Panel on Follow-up Care of Patients with Breast Cancer. Santa Margherita Ligure, IT.
2006. The role of weekly paclitaxel in the neoadjuvant and adjuvant settings in early breast cancer: The M. D. Anderson Cancer Center experience and other important clinical trials. Invited. Taipei International Breast Cancer Symposium. Taipei, TW.
2006. Tratamiento integral del cancer de mama. Invited. Simposium Medico de Oncologia. Monterrey, MX.
2006. Docetaxel-containing regimens in early-stage breast cancer: What to expect in 2006 and beyond. Invited. Taipei International Breast Cancer Symposium. Taipei, TW.
2006. Current strategies of hormonal treatment in early breast cancer. Invited. Taipei International Breast Cancer Symposium. Taipei, TW.
2006. Recent advances in systemic adjuvant therapy in early breast cancer. Invited. Taipei International Breast Cancer Symposium. Taipei, TW.
2006. Controversias en adyuvancia en cancer de mama. Invited. Sociedad Chilena de Cancerologia XVI Congreso. Pucon, CL.
2006. Chemotherapy in the metastatic setting: The value of circulating tumor cells in assessing response; when to use single sequential vs. combination chemotherapy vs. metronomic chemotherapy. Invited. Third Interamerican Breast Cancer Conference. Cancun, MX.
2006. Neuvas terapias biologicas en cancer de mama. Invited. X Aniversario de la Unidad de Oncologia Y Radioterapia del Hospital Centenario Miguel Hidalgo, VII Congreso de Oncologia y la XII Reunion de la Agrupacion Mexicana de Onco-Hematologia Pediatrica. Aguascalientes, MX.
2006. Adjuvant hormonotherapy in early breast cancer. Invited. VI Congreso Peruano de Mastologia. Lima, PE.
2006. Comprehensive management of breast cancer and innovations in non-cytotoxic medical therapy. Invited. Oncologia 2006, XXII Congreso Internacional de Medicine. Monterrey, MX.
2006. New drugs in breast cancer. Conference. VI Congreso Peruano de Mastologia. Lima, PE.
2006. Adjuvant therapy with trastuzumab in early breast cancer. Invited. VI Congreso Peruano de Mastologia. Lima, PE.
2006. Treatment of metastatic breast cancer: state of the art. Invited. 2nd International Symposium on Breast Cancer. Sao Paulo, BR.
2006. Neoadjuvant chemotherapy: the M. D. Anderson Cancer Center experience. Invited. 2nd International Symposium on Breast Cancer. Sao Paulo, BR.
2006. Adjuvant chemotherapy and hormonal therapy. Invited. 2nd International Symposium on Breast Cancer. Sao Paulo, BR.
2006. Neoadjuvant chemotherapy. Invited. XXIII Annual Meeting. Puerto Vallarta, MX.
2005. Quimioterapia adyuvante en cancer de mama. Invited. IX Jornadas Cientificas, Sociedad Medica del Instituto Oncologico "Dr. Luis Razeti". Caracas, VE.
2005. Adjuvant chemotherapy. Invited. Simposio Internacional Cancer de Mama 2005. Sao Paulo, BR.
2005. Who should receive adjuvant chemotherapy in early breast cancer?. Invited. Simposio Internacional Cancer de Mama 2006. Sao Paulo, BR.
2004. Estandares de adyuvancia en cancer de mama. Invited. IX Jornadas de Cancerologia de Occidente. Guadalajara, MX.
2004. Terapia hormonal nuevos farmacos. Invited. IX Jornadas de Cancerologia de Occidente. Guadalajara, MX.
2004. Estado actual del manejo hormonal en cancer de mama. Invited. XXIII Congreso Nacional de Oncologia of the Sociedad Mexicana de Oncologia. Merida, MX.
2004. Clinical development and recent findings of novel cytotoxics. Invited. European Society of Medical Oncology, Satellite Symposium. Vienna, AT.
2004. Neoadjuvant trials for HER2-positive breast cancer. Invited. National Surgical Adjuvant Breast and Bowel Project (NSABP) Group Meeting. Toronto, CA.
2004. Normal cardiac biopsy results following co-administration of doxorubicin, cyclophosphamide, and trastuzumab (Poster). Invited. American Society of Clinical Oncology 40th Annual Meeting. New Orleans, US.
2004. Indicaciones actuales de los inhibidores de aromatase. Invited. Sociedad de Oncologos del ISSSTE (SOISSSTE), Tercer Congreso Nacional. Oaxaca, MX.
2004. Anticuerpos monoclonales en cancer de mama. Invited. V Congreso Peruano de Mastologia. Lima, PE.
2004. Rol de los taxanos en tratamiento adyuvante y neoadyuvante. Invited. V Congreso Peruano de Mastologia. Lima, PE.
2004. Actualization y controversias en tratamiento hormonal en cancer de mama. Invited. V Congreso Peruano de Mastologia. Lima, PE.
2003. Clinical case studies. Invited. XXII Congreso Nacional de Oncologia of the Sociedad Mexicana de Estudios Oncologicos. Juriquilla, MX.
2003. Chemotherapy and biological modifiers in breast carcinoma. Invited. 1st International Congress on Advances in Chemotherapy, Radiotherapy, and Biological Modifiers in Cancer. Mexico City, MX.
2003. Novel taxoids. Invited. 2nd Annual The Future of Breast Cancer: An International Breast Cancer Congress. Banff, CA.
2003. Controversias del tratamiento sistemico del cancer de mama temprano. Invited. Academic Interchange Select Topics on Oncology. Puebla, MX.
2003. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Guadalajara, MX.
2003. The role of small molecules & new hormonal therapy, Symposium V, New Approaches & New Agents for the Future. Invited. V Madrid Breast Cancer Conference. Madrid, ES.
2003. The role of anthracyclines, Round Table II. Invited. V Madrid Breast Cancer Conference. Madrid, ES.
2003. Tratamiento neoadyuvante y adyuvante del cancer de mama desde la perspective de la medicina basada en la evidencia. Invited. XXVII Congress of the Spanish Society of Obstetrics and Gynecology. Madrid, ES.
2003. Factores pronosticos clinicos, y biologicos en cancer de mama. Invited. XXVII Congress of the Spanish Society of Obstetrics and Gynecology. Madrid, ES.
2003. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Tampico, MX.
2003. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Tijuana, MX.
2003. Cancer de mama metastasico: estado del arte. Invited. II Congreso Regional Andino de Oncologia Clinica. Panama City, PA.
2003. Cancer de mama operable: controversias en la terapia adyuvante. Invited. II Congreso Regional Andino de Oncologia Clinica. Panama City, PA.
2002. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Monterrey, MX.
2002. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Guadalajara, MX.
2002. Breast cancer review and treatment options. Invited. Academic Interchange Select Topics on Oncology. Mexico City, MX.
2002. Pathologically involved axillary nodes following primary chemotherapy in locally advanced breast cancer is an early biological prognostic factor of long-term outcome in patients with LABC: The University of Texas M. D. Anderson Cancer Center experience. Invited. 27th European Society for Medical Oncology Congress. Nice, FR.
2002. Chemotherapy in the metastatic setting. Invited. First Interamerican Breast Cancer Conference. Cancun, MX.
2002. Ongoing Clinical Trials in the Adjuvant Setting. Invited. First Interamerican Breast Cancer Conference. Cancun, MX.
2002. Hormonal treatments in breast cancer. Invited. Congress of the Mexican Mastology Association. Queretaro City, MX.
2002. Advances in the treatment of early and advanced breast cancer. Invited. 1st Scientific Symposium. Thessalonica, GR.
2001. New Agents in the Treatment of Metastatic Breast Cancer. Invited. 16th Asia Pacific Cancer Conference. Manila, PH.
2001. Resultados del Tratamiento Neoadyuvante y Adyuvante del Cancer de Mama. Invited. Congreso Nacional de Oncologia. Morelia, MX.
2001. Review of chemotherapy trial results: the Houston experience. Invited. Preoperative Systemic Therapy of Primary Breast Cancer Symposium. Biedenkopf a. d. Lahn, DE.
2001. Adjuvant therapy of early breast cancer. Invited. Arab International Cancer Congress 2001. Beirut, LB.
2001. Metastatic breast cancer: integrating new agents. Invited. Arab International Cancer Congress 2001. Beirut, LB.
2001. The bioethic and the oncology patient. Invited. University of Monterrey 1st International Bioethic Congress. Monterrey, MX.
2001. Quimioterapia neoadyuvante y quimioprofilaxia en cancer de mama. Invited. Sociedad de Ginecologia y Obstetricia de Monterrey, Profesor Conferenciante con el Tema. Monterrey, MX.
2001. New hormonal treatments for breast cancer. Invited. 6th International Coloquium of Oncology and Hematology. Oaxaca, MX.
2001. Early adjuvant treatment in breast cancer. Invited. 5th International Coloquium of Oncology and Hematology. Oaxaca, MX.
2000. Quimioterapia adyuvante estandar e intensiva. Invited. XXVII Symposium Internacional Mastologia 2000. Barcelona, ES.
2000. Quimioprevencion en cancer de mama. Invited. XIII Congreso Centroamericano y del Caribe de Oncologia y Congreso Integrado ONCO 2001. Tegucigalpa, HN.
2000. Nuevas drogas en el manejo de cancer de mama. Invited. XIII Congreso Centroamericano y del Caribe de Oncologia y Congreso Integrado ONCO 2000. Tegucigalpa, HN.
2000. Prevention and treatment of breast cancer: moving toward the new millennium. Invited. opening of M. D. Anderson International - Espana. Madrid, ES.
2000. Adjuvant/neo-adjuvant treatment of breast cancer. Invited. III Simposio de Revisiones en Cancer. Madrid, ES.
2000. Taxol vs. Taxotere. Invited. XI International Congress of Senology. Cancun, MX.
2000. Pamidronate in bone metastases. Invited. XI International Congress of Senology. Cancun, MX.
2000. Inflammatory breast cancer. Invited. XI International Congress of Senology. Cancun, MX.
2000. Breast cancer and pregnancy. Invited. XI International Congress of Senology. Cancun, MX.
2000. Trastuzumab (Herceptin) in the treatment of metastatic breast cancer. Invited. XI International Congress of Senology. Cancun, MX.
2000. Genetic counseling. Invited. XI International Congress of Senology. Cancun, MX.
2000. Tamoxifeno na quimioprevencao: a nova era do litigio legal em cancer de mama. Invited. III Seminario Controversias em Mastologia e VII Curso de Atualizacao em Mastologia do IFF/FIOCruz. Rio de Janeiro, BR.
1999. Avances en el tratamiento de la enfermedad metastasica en cancer de seno. Invited. la Asociacion de Enfermeria Oncologica Colombiana y la Asociacion Colombiana de Citologia. Bogota, CO.
1999. Aplicaciones clinicas y terapeuticas del HER2neu, Cancer 99, Las Sociedades Cientificas de Colombiana: de Cancerologia, de Mastologia, de Cuidados Paliativos, de Radioterapia, de Ginecologia, and las Asociacion Colombiana de Radioterapia. Invited. la Asociacion de Enfermeria Oncologica Colombiana y la Asociacion Colombiana de Citologia. Bogota, CO.
1999. Quimioprevencion en cancer de seno. Invited. la Asociacion de Enfermeria Oncologica Colombiana y la Asociacion Colombiana de Citologia. Bogota, CO.
1999. Breast cancer: a world challenge. Invited. Symposium El Cambio de Paradigmas de la Planificacion Familiar a la Salud Reproductiva. Mexico City, MX.
1999. Taxotere: tratamiento en cancer de mama y en combinacion. Invited. Primer Congreso Centroamericano y del Caribe de Mastologia. San Jose, CR.
1999. Dosis altas de quimioterapia. Invited. Seminario de Oncologia. Panama City, PA.
1999. Neuvas perspectivas en terapia adjuvante: papel de los taxoides, Simposio Sobre Cancer de Seno. Invited. Neuvos Agentes en el Tratamiento de Primera y Segunda Linea de31 Cancer de Mama Avanzado. Cartagena, CO.
1999. Nuevas drogas en cancer de mama. Invited. Seminario de Oncologia. Panama City, PA.
1999. Experiencia con cirugia conservadora en el cancer de mama localmente avanzado. Invited. XVIII Congreso Nacional de la Sociedad Espanola de Senologia y Patologia. Marbella, ES.
1999. Quimioprevencion del cancer de mama. Invited. Neuvos Agentes en el Tratamiento de Primera y Segunda Linea de31 Cancer de Mama Avanzado. Cartagena, CO.
1999. Taxotere as first-line therapy for women with metastatic breast cancer, estado actual y futuro del; tratamiento del cancer de ovario, Jornadas Medicas. Invited. XXXVIII Aniversario Hospital de Oncologia. Mexico City, MX.
1999. Benefits of adjuvant doxorubicin/cyclophosphamide-containing therapy in women with breast cancer by age: The University of Texas M. D. Anderson Cancer Center experience. Invited. American Society of Clinical Oncology 35th Annual Meeting. Atlanta, US.
1999. Manejo multidisciplinario del carcinoma de mama localmente avanzado. Invited. X Congreso Internacional de Cirugia General, Surgical Oncology for the General Surgeon. Monterrey, MX.
1999. Nuevas estrategias en el tratamiento medico de carcinoma de mama. Invited. X Congreso Internacional de Cirugia General, Surgical Oncology for the General Surgeon. Monterrey, MX.
1998. Protocolos de quimioterapia en el cancer de mama temprano y en el cancer avanzado. Invited. Symposium Cancer de Mama--Una Vision Actual. Monterrey, MX.
1998. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Invited. 23rd Congress European Society of Medical Oncology. Athens, GR.
1998. High-dose chemotherapy in breast cancer. Invited. II Congreso Nacional de Senologia y Patologia Mamaria. Vigo, ES.
1998. New dimensions in breast cancer. Invited. II Congreso Nacional de Senologia y Patologia Mamaria. Vigo, ES.
1998. Paclitaxel as a single-agent therapy in women > 65 years with previously treated metastatic breast cancer: the M. D. Anderson Cancer Center experience. Invited. IV International Conference on Geriatric Oncology. Rome, IT.
1998. Tamoxifen as primary therapy in combined modality treatment of elderly patients with locally advanced breast cancer. Invited. IV International Conference on Geriatric Oncology. Rome, IT.
1998. Adjuvant anthracycline-containing therapy in women > 65 years with breast cancer: the M. D. Anderson Cancer Center experience. Invited. IV International Conference on Geriatric Oncology. Rome, IT.
1998. High-dose chemotherapy in metastatic breast cancer. Invited. X Latinoamerican Congress and VI Argentinean Congress of Mastology. Buenos Aires, AR.
1998. Management of patients with locally advanced breast cancer. Invited. X Latinoamerican Congress and VI Argentinean Congress of Mastology. Buenos Aires, AR.
1998. New agents in the management of breast cancer. Invited. X Latinoamerican Congress and VI Argentinean Congress of Mastology. Buenos Aires, AR.
1998. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Invited. 17th International Cancer Congress. Rio de Janeiro, BR.
1998. Combined modality treatment of locally advanced breast cancer in elderly patients using tamoxifen as primary therapy. Invited. 17th International Cancer Congress. Rio de Janeiro, BR.
1998. High-dose chemotherapy plus hematopoietic stem cell rescue in breast cancer. Invited. II International Conference. Oaxaca, MX.
1998. The role of second-line chemotherapy in advanced breast cancer, Academic, Global, Virtual: Towards Evidence-Based Paradigms. Invited. Breast Cancer International Research Group. Edmonton, CA.
1998. Combined modality treatment of locally advanced breast cancer in elderly patients using tamoxifen as primary therapy. Invited. American Society of Clinical Oncology 34th Annual Meeting. Los Angeles, US.
1997. Neoadjuvant Chemotherapy for Stage III Breast Cancer: Institutional Experiences. Invited. 1st International Symposium GEICAM Group. Zaragoza, ES.
1997. Docetaxel in combination with doxorubicin as a first treatment in breast cancer. Invited. V Congreso Venezolano de Mastologia, Pto. Pto. La Cruz, VE.
1997. Quimioterapia en cancer de mama diseminado, primera y segunda linea de tratamiento. Invited. Sociedad Chilena de Mastologia IV Congreso. Santiago, CL.
1997. Quimioterapia adyuvante, altas dosis. Invited. Sociedad Chilena de Mastologia IV Congreso. Santiago, CL.
1996. Locally advanced breast cancer. Invited. VII Congreso, Venezolano de Oncologia. Caracas, VE.
1996. Taxotere (docetaxel) in metastatic breast cancer. Invited. Grupo Oncologia de Investigacion Ecuatoriano. Guayaquil, EC.
1996. Natural history and prognostic factors in breast cancer. Invited. Grupo Oncologia de Investigacion Ecuatoriano. Guayaquil, EC.
1996. Management of locally advanced breast cancer. Invited. Grupo Oncologia de Investigacion Ecuatoriano. Guayaquil, EC.
1996. High-dose chemotherapy in breast cancer. Invited. Congresso Sul-Brasileiro de Mastologia. Porto Alegre, BR.
1996. Quimioterapia primaria. Invited. Congresso Sul-Brasileiro de Mastologia. Porto Alegre, BR.
1996. Tratamiento farmacologico del cancer de mama. Invited. 1ER Congreso Internacional. San Miguel, MX.
1996. The treatment of breast cancer with Taxotere. Invited. Annual Meeting of the Brazilian Oncology Society. Salvador, BR.
1996. Avances en la terapeutica sistemic para el manejo del cancer mamario. Invited. IV Curso Internacional Avances en la Terapeutica del Cancer de la Mujer. Mexico City, MX.
1996. Adjuvant treatment of breast cancer. Invited. The University of Texas M. D. Anderson Cancer Center International Medical Oncology Conference II. Houston, US.
1996. Docetaxel (Taxotere) therapy in paclitaxel-resistant metastatic breast cancer. Invited. American Society of Clinical Oncology 32nd Annual Meeting. Philadelphia, US.
1996. Taxoids in the management of breast cancer. Invited. 9th International Congress on Breast Diseases, Satellite Symposium. Houston, US.
1996. Neoadyuvancia en el tratamiento del cancer de mama temprano y avanzado. Invited. X Congreso CRILA-Panama. Panama City, PA.
1996. Tratamiento adyuvante sistemico del cancer temprano de la glandula mamaria. Invited. Conferencia Magistral de la Sociedad Mexicana de Estudios Oncologicos. Monterrey, MX.
1996. Management of advanced cancer I: breast cancer. Invited. International Taxotere Symposium. Prague, CZ.
1995. Docetaxel in non-small cell lung cancer and breast cancer. Invited. Uruguayan Clinical Oncology Society. Montevideo, UY.
1995. Docetaxel (Taxotere) therapy in anthracycline/anthracenedione- or paclitaxel-resistant metastatic breast cancer (oral presentation). Invited. American Society of Clinical Oncology 31st Annual Meeting. Los Angeles, US.
1995. Tratamiento adyuvante sistemico para cancer de mama. Invited. The University of Texas M. D. Anderson Cancer Center International Medical Oncology Conference. Houston, US.
1995. Taxanos. Invited. The University of Texas M. D. Anderson Cancer Center International Medical Oncology Conference. Houston, US.
1995. Breast cancer. Invited. Segundo Coloquio de Hemato-Oncologia. Merida, MX.
1995. New drugs: Taxotere. Invited. Congreso Nacional de Oncologia Espanola. Granada, ES.
1994. Taxotere (docetaxel) in the treatment of anthracycline/ anthracenedione-refractory metastatic breast cancer: combined results of two U.S. phase II studies. Invited. 19th Congress of the European Society of Medical Oncology. Lisbon, PT.
1994. Agentes antineoplasicos nuevos en el tratamiento del cancer de mama avanzado. Invited. IV Jornadas de Cancerologia de Occidente. Puerto Vallarta, MX.
1994. Treatment of breast cancer. Invited. XXI Annual Meeting of the Peruvian American Medical Society. Lima, PE.
1994. Phase II study of docetaxel in anthracycline-refractory metastatic breast cancer. Invited. American Society of Clinical Oncology 30th Annual Meeting. Dallas, US.
1994. Phase II study of Taxotere in anthracycline-refractory metastatic breast cancer. Invited. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, NL.
1994. Taxoids in breast cancer. Invited. XI Reunion Nacional Medica del Instituto Nacional de Cancerologia. Aguascalientes, MX.
1993. Phase II study of Taxotere in refractory metastatic breast cancer. Invited. 7th European Conference on Clinical Oncology and Cancer Nursing. Jerusalem, IL.
1993. New therapies or future directions in systemic therapy for breast cancer. Invited. Breast Cancer Conference. Bogota, CO.
1993. Controversies in adjuvant systemic therapy of breast cancer. Invited. Breast Cancer Conference. Bogota, CO.
1993. Comprehensive management of locally advanced and inflammatory breast cancer. Invited. Breast Cancer Conference. Bogota, CO.
1993. Management of bone metastasis and its complications. Invited. Breast Cancer Conference. Bogota, CO.
1993. Actual investigations on breast cancer. Invited. IV Congreso Nacional de Ginecologia y Obstetricia. Tijuana, MX.
1993. Phase II study of Taxotere in patients with anthracycline-resistant metastatic breast cancer. Invited. 18th International Congress of Chemotherapy. Stockholm, SE.
1993. Chemo-prevention in patients with high risks for breast cancer. Invited. Congresos Integrados Latino Americanos de Cancerologia (CILAX XI). Cancun, MX.
1992. New antineoplastic agents in breast cancer. Invited. First International Course in Breast Cancer. Monterrey, MX.
1992. High-dose chemotherapy in patients with advanced breast cancer. Invited. First International Course in Breast Cancer. Monterrey, MX.
1992. Treatment of breast cancer stage I, II, stage IV, II. Invited. Curso Internacional de Ginocelogia Oncologica y de Neoplasias de la Glandula Mamaria. Mexico City, MX.

Formal Peers

2013. Multidisciplinary Breast Cancer Management Course. Invited. Panama City, PA.
2013. Neoadjuvant setting: beyond locally advanced tumors, clinical impact and advantages of neoadjuvant trials. Invited. Madrid, ES.
2012. Recent Advances in the treatment of breast cancer. Invited. Corpus Christi, TX, US.
2012. Update in Multidisciplinary Treatment of Breast Cancer. Invited. Soth Padre Island, TX, US.
2012. HER2+ Breast Cancer Management: Practical Strategies for Everyday Use. Invited. Melbourne, FL, US.
2012. Pharmacogenomics in the treatment of early breast cancer. Invited. Chicago, IL, US.
2012. Spotlight on Recurrent Metastatic Breast Cancer. Invited. Teaneck, NJ, US.
2012. Management of Anthracycline Taxane resistant MBC: Current Therapeutic Options. Visiting, Delhi, IN.
2012. Metastatic Breast Cancer CME Lecture Series. Invited. Alexandria, VA, US.
2012. Metastatic Breast Cancer CME Lecture Series. Invited. Columba, MO, US.
2011. IBC - Diagnosis and Staging. Invited. Nassau Bay, TX, US.
2010. Clinical Pathways Development for Early Stage Breast Cancer. Invited. Cincinnati, OH, US.
2010. Clinical Pathways Development for Early Stage Breast Cancer. Invited. Cincinnati, OH, US.
2010. State of the Art Breast Cancer Care - The Next Decade of Novel Therapies. Invited. Detroit, MI, US.
2010. State of the Art Breast Cancer Care - The Next Decade of Novel Therapies. Invited. Fountain Valley, CA, US.
2010. Treating the HER2-Positive Breast Cancer Patient: Challenges and Controversies. Invited. Stony Brook, NY, US.
2010. Treating the HER2 Positive Breast Cancer Patient: Challenges and Controversies. Invited. New York, NY, US.
2009. Putting the Pieces Together: Breast Cancer Management in 2009. Invited. Tulsa, OK, US.
2009. Individualizing Adjuvant Therapy for Early Breast Cancer. Invited. Corpus Christi, TX, US.
2009. Putting the Pieces Together: Breast Cancer Management in 2009. Invited. Dallas, TX, US.
2009. Papel de las terapias biologicas, triple negativo. usa de herceptin, una experiencia mexicana. Invited. Ixtapan de la Sal, MX.
2009. Current Status of Chemotherapy, Endocrine and Biological Therapy for Early Breast Cancer: Development and Intregrations of New Treatment Strategies. Invited. Jackson, MS, US.
2009. Breast Cancer Management: Updates, Advances and New Options. Invited. Chihuahua, MX.
2009. Pharmacogenomics: Emerging Diagnostic Test to Predict Disease Relapse and Benefit to Adjuvant and Primary Systemic Therapy (PST) in Patients with Early Breast Cancer. Invited. St. Louis, MO, US.
2009. Pharmacogenomics: Emerging Diagnostic Test to Predict Disease Relapse and Benefit to Adjuvant and Primary Systemic Therapy (PST) in Patients with Early Breast Cancer. Invited. St. Louis, MO, US.
2009. Tratamiento Neoadyuvante Cancer de Mama. Invited. Mexico City, MX.
2009. Role of Gemzar in Metastasic Breast Cancer after Antracyclines. Visiting. Mexico City, MX.
2009. Early Breast Cancer Management: Updates, Advances and New Options 2008. Invited. Austin, TX, US.
2009. Neoadjuvant and adjuvant treatment of HER 2 negative breast cancer management. Invited. Sao Paulo, BR.
2008. Research projects in oncology. Invited. Mexico City, MX.
2008. Breast Cancer Managment: Updates, Advances and New Options. Invited. Pensacola, FL, US.
2008. Current Standards and New Advances in the Treatment of HER2-positive Breast Cancer. Invited. Brockton, MA, US.
2008. Optimal Use of Markers to Develop Therapeutic Strategies and Monitor Treatment Response in Metastatic Breast Cancer. Invited. Rochester, NY, US.
2008. Current and Evolving Therapeutic Strategies in the Management of Metastatic Breast Cancer. Invited. Rochester, NY, US.
2008. Breast Cancer Management: Updates, Advances and New Options. Invited. Philadelphia, PA, US.
2008. Role of Oncotype DX in Node Positive Breast Cancer. Invited. Redwood City, CA, US.
2008. Breast Cancer Management: Updates, Advances and New Options. Invited. Houston, TX, US.
2008. Breast Cancer Management: Updates, Advances and New Options. Invited. Houston, TX, US.
2008. The Great Debate: Clinical Practice Dilemmas in Invastive Breast Cancer. Invited. Las Vegas, NV, US.
2008. Current Standards and New Advances in Treatment of HER2 Positive Breast Cancer. Invited. Columbia, SC, US.
2008. Optimal Use of Markers to Develop Therapeutic Strategies and Monitor Treatment Response in MBC. Invited. Jupiter, FL, US.
2008. Current Standards and New Advances in the Treatment of HER2+ Breast Cancer. Invited. Little rock, AR, US.
2008. Novel Preoperative Therapy Strategies. Invited. Minneapolis, MN, US.
2007. Development and Integration of Treatment Strategies in Breast Cancer. Invited. Daytona Beach, FL, US.
2007. Development and Integration of Treatment Strategies in Breast Cancer. Invited. La Jolla, CA, US.
2007. Current Status of Chemotherapy and Endocrine Therapy for Early Stage Breast Cancer. Invited. Milwaukee, WI, US.
2007. Development and Integration of Treatment Strategies in Breast Cancer. Invited. Tulsa, OK, US.
2007. HER2 Targeting Agents in Clinical Practrice Improving Patient Outcomes from Early to Advanced Breast Cancer. Invited. Laredo, TX, US.
2007. HER2 targeting agents in clinical practice improving patient outcomes from early to advanced breast cancer. Invited. Glendale, CA, US.
2007. HER2 targeting agents in clinical practice improving patient outcomes from early to advanced breast cancer. Invited. Corpus Christi, TX, US.
2007. Adjuvant and metastatic breast cancer. Invited. Canton, GA, US.
2007. Utilizing genomics in early-stage breast cancer. Invited. Wilmington, NC, US.
2007. HER2 targeting agents in clinical practice improving patient outcomes from early to advanced breast cancer. Invited. Newport Beach, CA, US.
2007. Post-ASCO update on utilizing genomics in early-stage breast cancer. Invited. Winston-Salem, NC, US.
2007. Utilizing genomics in early-stage breast cancer. Invited. Cary, NC, US.
2007. Post-ASCO update/overview on utilizing genomics in early-stage breast cancer. Invited. Greensboro, NC, US.
2007. Adjuvant and metastatic breast cancer. Invited. Melbourne, FL, US.
2007. Adjuvant and metastatic breast cancer. Invited. Phoenix, AZ, US.
2007. Adjuvant and metastatic breast cancer. Invited. Phoenix, AZ, US.
2007. New options in the treatment of metastatic breast cancer. Invited. Oklahoma City, OK, US.
2007. Utilizing genomics in early-stage breast cancer. Invited. Los Angeles, CA, US.
2007. Integrating novel therapeuticf approaches into the treatment of breast cancer. Invited. Cincinnati, OH, US.
2006. Managing HER2-positive breast cancer from early to metastatic disease. Invited. Daytona Beach, FL, US.
2006. Integrating novel therapeutic approaches into the treatment of breast cancer. Invited. Birmingham, AL, US.
2006. Integrating novel therapeutic approaches into the treatment of breast cancer. Invited. Philadelphia, PA, US.
2006. Integrating novel therapeutic approaches into the treatment of breast cancer. Invited. Tulsa, OK, US.
2006. Pharmacogenomics: Emerging diagnostic test to predict benefit or response to adjuvant primary systemic therapy (PST) in patients with breast cancer. Invited. Munich, DE.
2006. Adjuvant therapy of breast cancer. Invited. Tampa, FL, US.
2006. Highlights from the 2005 SABCS: Systemic & targeted therapies. Invited. Duarte, CA, US.
2006. Rational use of chemotherapy in the treatment of. Invited. Cleveland, OH, US.
2006. Adjuvant and neoadjuvant hormonal therapy. Invited. Cleveland, OH, US.
2006. Adjuvant therapy of breast cancer. Invited. Costa Mesa, CA, US.
2006. Therapy for metastatic breast cancer. Invited. Costa Mesa, CA, US.
2006. Welcome and Overview (Program Chairperson). Invited. Costa Mesa, CA, US.
2006. Therapy for metastatic breast cancer. Invited. Tampa, FL, US.
2006. Rational use of chemotherapy in the treatment of early-stage breast cancer. Invited. Stony Brook, NY, US.
2006. Dose dose-dense make sense?. Invited. Pensacola, FL, US.
2005. The evolving role of HER2-targeted therapies in breast cancer. Invited. Fort Lauderdale, FL, US.
2005. The evolving role of HER2-targeted therapies in breast cancer. Invited. Charleston, SC, US.
2004. Adjuvant treatment of early high-risk breast cancer: current status and controversies. Invited. Miami, FL, US.
2004. The treatment of early-stage breast cancer. Invited. Los Angeles, CA, US.
2004. The treatment of early-stage breast cancer. Invited. Los Angeles, CA, US.
2004. Post-ASCO update on the treatment of breast cancer. Invited. Burbank, CA, US.
2004. The management of HER/2-positive metastatic breast cancer. Invited. Tampa, FL, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Invited. Shreveport, LA, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Invited. Davenport, FL, US.
2004. Evolving concepts: hormonal therapy in early breast cancer. Invited. Denver, CO, US.
2004. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Invited. Daytona Beach, FL, US.
2004. Update on management of metastatic breast cancer. Invited. Lewiston, ME, US.
2004. Update in adjuvant and primary therapy in the management of early breast cancer. Invited. St. Louis, MO, US.
2004. Neoadjuvant chemotherapy: the indications and the evidence. Invited. Louisville, KY, US.
2004. Evolving concepts in adjuvant hormonal and chemotherapy in early breast cancer: what’s new?. Invited. St. Louis, MO, US.
2004. Breast cancer treatment options: 2004 overview. Invited. St. Louis, MO, US.
2004. Post-San Antonio Breast Cancer Symposium update. Invited. Tallahassee, FL, US.
2004. Post-San Antonio Breast Cancer Symposium update. Invited. Albany, GA, US.
2004. Post-San Antonio Breast Cancer Symposium update. Invited. Thomasville, GA, US.
2003. Controversy in adjuvant treatment approaches with dose-intense vs. dose-dense therapy in metastatic breast cancer. Invited. Tampa, FL, US.
2003. Controversy in adjuvant treatment approaches with dose-intense vs. dose-dense therapy in metastatic breast cancer. Invited. Tampa, FL, US.
2003. Adjuvant chemotherapy for breast cancer. Invited. Roslyn, NY, US.
2003. Understanding targeted biologic therapies in the treatment of HER2-positive metastatic breast cancer. Invited. Lake Charles, LA, US.
2003. Nancy Floyd Haworth Lectureship series. Invited. Albuquerque, NM, US.
2003. New options in the treatment of early-stage breast cancer. Invited. San Diego, CA, US.
2003. New options in the treatment of early-stage breast cancer. Invited. Glendale, CA, US.
2003. New options in the treatment of early-stage breast cancer. Invited. Santa Monica, CA, US.
2003. New options in the treatment of early-stage breast cancer. Invited. Burbank, CA, US.
2003. New options in the treatment of early-stage breast cancer. Invited. Panorama City, CA, US.
2003. Post-ASCO update on adjuvant treatment for early-stage and metastatic breast cancer. Invited. Miami, FL, US.
2003. Post-ASCO update on adjuvant treatment for early-stage and metastatic breast cancer. Invited. Miami, FL, US.
2003. Advances in the treatment of metastatic breast cancer. Invited. Olney, MD, US.
2003. Advances in the treatment of metastatic breast cancer. Invited. Washington, US.
2003. Management of patients with HER-2/neu metastatic breast cancer. Invited. New Orleans, LA, US.
2003. Management of patients with HER-2/neu metastatic breast cancer. Invited. New Orleans, LA, US.
2003. Adjuvant breast cancer: What’s new?. Invited. Park Ridge, IL, US.
2003. Adjuvant therapy in early breast cancer. Invited. Santa Cruz, CA, US.
2003. Adjuvant therapy in early breast cancer. Invited. Oakland, CA, US.
2003. Adjuvant therapy in early breast cancer. Invited. San Francisco, CA, US.
2003. New Developments in the treatment of breast cancer. Invited. Washington, US.
2003. Adjuvant chemotherapy and hormonotherapy in early breast cancer: overview. Invited. Hudson, FL, US.
2003. Adjuvant chemotherapy and hormonotherapy in early breast cancer: overview. Invited. Orlando, FL, US.
2002. New advances in early breast cancer. Invited. Chicago, IL, US.
2002. New options in the treatment of early-stage breast cancer. Invited. Harvey, IL, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. San Diego, CA, US.
2002. Advances in the treatment of early-stage breast cancer. Invited. Richmond, VA, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Arlington, VA, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Fairfax, VA, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Washington, DC, US.
2002. Current strategies with adjuvant/neoadjuvant breast cancer patients. Invited. Raleigh, NC, US.
2002. New options in the treatment of early-stage breast cancer. Invited. Honolulu, HI, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Hilo, HI, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Portland, OR, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Providence, RI, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Providence, RI, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Providence, RI, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Torrance, CA, US.
2002. New options in the treatment of early-stage breast cancer. Invited. Glendale, CA, US.
2002. Advances in the treatment of metastatic breast cancer. Invited. Fullerton, CA, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Winston Salem, NC, US.
2001. New agents in the management of metastatic breast cancer. Invited. Albany, NY, US.
2001. HER2-driven disease in breast cancer. Visiting. Orlando, FL, US.
2001. Adjuvant treatment for breast cancer. Invited. Los Angeles, CA, US.
2001. Post ASCO update in breast cancer. Invited. Covina, CA, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Los Angeles, CA, US.
2001. Treatment of metastatic breast cancer. Invited. Marshfield, WI, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Torrance, CA, US.
2001. Post ASCO update in metastatic breast cancer. Invited. Burbank, CA, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Los Angeles, CA, US.
2001. New developments in the treatment of breast cancer. Invited. Sacramento, CA, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Schenectady, NY, US.
2001. Metastatic breast cancer: integrating new treatment strategies into patient care. Invited. La Jolla, CA, US.
2001. Advances in the treatment of metastatic breast cancer. Invited. Miami, FL, US.
2000. Adjuvant therapy: predictors of response and outcome. Invited. Kona, HI, US.
2000. Adjuvant therapy: beyond dose-intense therapy. Invited. Kona, HI, US.
2000. Advances in the treatment of metastatic breast cancer. Invited. Spokane, WA, US.
2000. Advances in the treatment of metastatic breast cancer. Invited. Ft. Myers, FL, US.
2000. Advances in the treatment of metastatic breast cancer. Invited. Orlando, FL, US.
2000. What should be the treatment of choice for inflammatory breast cancer and other locally advanced breast cancers?. Invited. Jacksonville, FL, US.
2000. What should be the treatment of choice for metastatic breast cancer?. Invited. Jacksonville, FL, US.
2000. Adjuvant therapy for early-stage breast cancer: stage I-III. Invited. Istanbul, TR.
2000. Advancements in the treatment of breast cancer. Invited. Pittsburgh, PA, US.
2000. Advancements in the treatment of breast cancer. Invited. Morgantown, WV, US.
1999. Post-ASCO update on metastatic breast cancer. Invited. Denver, CO, US.
1999. Latest treatment in breast cancer. Invited. Jacksonville, FL, US.
1999. Latest treatment in breast cancer. Invited. Gainesville, FL, US.
1999. Docetaxel/doxorubicin combinations. Invited. Amelia Island, FL, US.
1999. Advances in the treatment of metastatic breast cancer. Invited. Minneapolis, MN, US.
1999. Recent advances in the treatment of metastatic breast cancer. Invited. Yuma, AZ, US.
1999. Tamoxifen for the prevention of breast cancer. Visiting. Houston, TX, US.
1999. Advances in the treatment of metastatic breast cancer. Invited. LaJolla, CA, US.
1999. Advances in the treatment of metastatic breast cancer. Invited. Fullerton, CA, US.
1999. New agents in the treatment of metastatic breast cancer. Invited. Tampa, FL, US.
1999. Recent advances in the treatment of breast cancer. Invited. Orange, CA, US.
1999. New therapies in the prevention and treatment of breast cancer. Invited. Baton Rouge, LA, US.
1998. New agents in the management of metastatic breast cancer. Invited. New York, NY, US.
1998. Clinical issues in the management of breast cancer. Visiting. Houston, TX, US.
1998. New agents in the treatment of breast cancer. Invited. Miami, FL, US.
1998. Advances in the treatment of breast cancer. Invited. Beverly Hills, CA, US.
1998. Advances in the treatment of breast cancer. Invited. Pasadena, CA, US.
1997. Advances in the treatment of breast cancer. Invited. Las Vegas, NV, US.
1997. Review of taxanes in breast cancer. Invited. San Diego, CA, US.
1997. Advances in the treatment of refractory metastatic breast cancer. Invited. Cincinnati, OH, US.
1997. Advances in the treatment of breast cancer. Invited. Tulsa, OK, US.
1997. Advances in the treatment of breast cancer. Invited. Southfield, MI, US.
1997. The development of Taxotere. Invited. Cleveland, OH, US.
1997. Advances in the treatment of breast cancer. Invited. San Francisco, CA, US.
1997. Advances in the treatment of refractory metastatic breast cancer. Invited. Atlanta, GA, US.
1997. The M. D. Anderson experience with new agents in the management of metastatic breast cancer. Invited. Walnut Creek, CA, US.
1997. Advances in the treatment of breast cancer. Invited. Lebanon, NH, US.
1997. Advances in the treatment of breast cancer. Invited. Sacramento, CA, US.
1997. Advances in the treatment of breast cancer. Invited. Redding, CA, US.
1997. Advances in the treatment of breast cancer. Invited. Honolulu, HI, US.
1997. Advances in the treatment of breast cancer. Invited. Honolulu, HI, US.
1996. New agents in the management of metastatic breast cancer. Invited. San Francisco, CA, US.
1996. Advancements in the treatment of breast cancer. Invited. Jamaica, NY, US.
1996. Metastatic breast cancer. Invited. Rochester, NY, US.
1996. Anthracycline-resistant breast cancer. Invited. New York, NY, US.
1996. Taxanes in breast cancer. Invited. Ottawa, CA.
1996. Implications of New Therapies on Health Care Costs. Invited. Ottawa, CA.
1996. Taxanes in metastatic breast cancer. Invited. Tampa Bay, FL, US.
1996. Oncology Day. Invited. Ottawa, CA.
1996. Management of refractory metastatic breast cancer with the use of taxanes. Invited. Cleveland, OH, US.
1996. The taxanes in breast cancer. Invited. Kingston, CA.
1996. The taxanes in breast cancer. Invited. Toronto, CA.
1994. Cancer de mama y genetica. Invited. Monterrey, MX.
1993. Taxol and breast cancer. Invited. Philadelphia, PA, US.
1993. Taxol and breast cancer. Invited. Newark, DE, US.
1993. Current developments in the treatment of metastatic breast cancer: implications for the use of taxanes. Invited. Silver Springs, MD, US.

Less

Grant & Contract Support

Date:	2022 - 2029
Title:	A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
Funding Source:	Dana-Farber Cancer Institute
Role:	PI
ID:	2022-0484

Date:	2021 - 2028
Title:	A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT)
Funding Source:	Dana-Farber Cancer Institute
Role:	PI
ID:	2021-0792

Date:	2021 - 2028
Title:	Phase 2 Single-Arm, Open-label, Pilot Trial Evaluating ZW25 in Patients with Low Risk HER2/neu Positive (HER2+) Breast Cancer (BC)
Funding Source:	Zymeworks
Role:	PI
ID:	2020-0358

Date:	2020 - 2027
Title:	Randomized, Double-blinded, Ph III study of Pembrolizumab vs Placebo in combo with Neoadjuvant Chemotherapy and adjuvant endocrine therapy for the treatment ER+/HER2- Breast Cancer (KEYNOTE-756) MK-3475-756-0083
Funding Source:	Merk
Role:	PI
ID:	2020-0012

Date:	2019 - 2026
Title:	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2- negative, early breast cancer (NATALEE)
Funding Source:	Novartis
Role:	PI
ID:	00007733

Date:	2019 - 2026
Title:	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (NATALEE)
Funding Source:	Novartis
Role:	PI
ID:	2018-1031

Date:	2019 - 2025
Title:	UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
Funding Source:	NCI
Role:	Investigator
ID:	UG1CA233329

Date:	2017 - 2023
Title:	SIV Division of Cancer Medicine Genentech SIV Alliance (SIV- A Phase II Study of Trip)
Funding Source:	Genetech Inc
Role:	Investigator
ID:	2016-0916

Date:	2017 - 2023
Title:	SIV Division of Cancer Medicine Genentech SIV Alliance (SIV- A Phase II Study of Trip
Funding Source:	Genetech Inc
Role:	Investigator

Date:	2017 - 2024
Title:	PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Funding Source:	Alliance for Clinical Trials Oncology Foundation
Role:	PI
ID:	2016-0022

Date:	2015 - 2024
Title:	A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer
Funding Source:	Johns Hopkins University
Role:	PI
ID:	2014-0363

Date:	2015 - 2024
Title:	A Randomized, Multicenter, Open-Label, Two Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared with Chemotherapy Plus Trastuzumab and Pertuzumab for Patients with Her2- Positive Breast Cancer
Funding Source:	Hoffman-La Roche Inc
Role:	PI
ID:	2014-0688

Date:	2014 - 2017
Title:	A Randomized, Phase II, Multicenter, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of AKT, in Combination with Paclitaxel as Front-Line Treatment for Patients with Metastatic Triple-Negative Breast Cancer
Funding Source:	Genetech Inc
Role:	PI
ID:	2014-0192

Date:	2014 - 2017
Title:	A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole plus GDC-0032 versus Letrozole plus Placebo in Postmenopausal Women with ER-Positive/HER-2
Funding Source:	Lorelei
Role:	PI

Date:	2014 - 2017
Title:	A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole plus GDC-0032 versus Letrozole plus Placebo in Postmenopausal Women with ER-Positive/HER-2 Negative, Early Stage Breast Cancer
Funding Source:	2014-0580
Role:	PI
ID:	2014-0580

Date:	2014 - 2024
Title:	A randomized Phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)
Funding Source:	Dana-Farber Cancer Institute
Role:	PI
ID:	2013-0957

Date:	2011 - 2015
Title:	A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of MetMab in combination with paclitaxel and bevacizumab in patients with metastatic, triple-negative breast cancer
Funding Source:	Genentech Inc
Role:	PI
ID:	CS2011-00034819JW 01

Date:	2011 - 2013
Title:	A Phase II randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer NSABPFB-7
Funding Source:	NSABP
Role:	PI
ID:	CS2011-00034589RG 01

Date:	2010 - 2018
Title:	A Phase II, Open Label study of Efficacy of TKI258 (Dovitinib Lactate) in Patients Who Have Received up to two Chemotherapy Lines for Metastatic HER2-negative Inflammatory Breast Cancer
Funding Source:	Novartis
Role:	PI
ID:	CS2010-00033608

Date:	2010 - 2012
Title:	A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive
Funding Source:	NSABP
Role:	PI
ID:	NSABP B-46 1

Date:	2009 - 2013
Title:	A multicenter phase III CT randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab
Funding Source:	The Cancer International Research Group (CIRG)
Role:	PI
ID:	CS209-00024574EB

Date:	2009 - 2011
Title:	Determination of HER2 Tumor Status by Circulating Tumor Cells (CTC) Analysis
Funding Source:	Genentech Inc
Role:	PI
ID:	LS2008-00022689JW

Date:	2008 - 2013
Title:	A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer
Funding Source:	NSABP
Role:	PI
ID:	5-U10-CA012027-37

Date:	2008 - 2013
Title:	Human Breast Cancer Stem Cell Surrogates
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA138239 02

Date:	2007 - 2010
Title:	Morphine versus Methadone as First Line Strong Opioid for Cancer Pain
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1-R01CA124481-01A1

Date:	2006 - 2010
Title:	Methylphenidate for Fatigue in Advanced Cancer Patients
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1-R01 NR010162-01A1

Date:	2006 - 2011
Title:	A phase III CT, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer
Funding Source:	Genentech, Inc
Role:	PI
ID:	CS2006-00016906SS

Date:	2006 - 2011
Title:	Early Therapeutics Development with Phase II Emphasis
Funding Source:	NIH/NCI
Role:	PI
ID:	N01-CM-62202 09

Date:	2004 - 2011
Title:	RegistHER: an observational cohort study of patients with HER2-positive metastatic breast cancer
Funding Source:	Genentech, Inc
Role:	PI
ID:	CS2004-00011793DH

Date:	2004 - 2007
Title:	Development and validation of gene-expression profile-based tests that predict pathologic complete response to preoperative chemotherapy for breast cancer
Funding Source:	NIH
Role:	Collaborator
ID:	1-R01-CA106290-01A1

Date:	2003 - 2008
Title:	Pain and Symptoms of Cancer: Assessment and Treatment
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5 R01 CA26582 24

Date:	2003 - 2010
Title:	A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphamide followed by taxol plus herceptin in node positive breast cancer patients who have tumors that overexpress HER2
Funding Source:	NSABP
Role:	PI
ID:	1U10 CA012027 01

Date:	2002 - 2004
Title:	Pilot study of biomarker modulation with a COX-2 inhibitor using ductal lavage in women at high risk for breast cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R03-CA 097557-01

Date:	2002 - 2012
Title:	A phase II trial of arimidex plus zoladex in the treatment of hormone receptor positive carcionoma of the breast in premenopausal women
Funding Source:	AstraZeneca
Role:	PI
ID:	CS2002-00007013DH-01

Date:	2002 - 2007
Title:	PRCC/MDACC Partners for Excellence in Cancer Research
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	CA096300-04, RFA-CA-02-005

Date:	2002 - 2014
Title:	Multicenter phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzamab and with docetaxel platinum salts and trastuzamab in the treatment of node positive and high risk node negative adjuvant patients with operable breast cancer continuing the Her2neu alteration
Funding Source:	Breast Cancer International Research Group
Role:	PI
ID:	CS01-269DH-01

Date:	2002 - 2005
Title:	Pilot Research Project B: EGFR, ErbB2 and 110 kD-sEGFR proteins in sera and breast tissues of Hispanic women diagnosed with breast cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	RFA-CA-02-005

Date:	1994 - 2001
Title:	Pain Management Skills for Minority Breast Cancer Patients
Funding Source:	Department of Defense Breast Cancer Research Program AIBS #2551
Role:	Collaborator
ID:	DAMD17-94-J-4233

CV information above last modified May 07, 2025

Vicente Valero, M.D., F.A.C.P.

About Dr. Vicente Valero

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Editorials

Abstracts

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Vicente Valero, M.D., F.A.C.P.

About Dr. Vicente Valero

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Editorials

Abstracts

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer